Title page

Wnt signaling and drug resistance in cancer

Zheng Zhong[1,2], David M. Virshup[2,3]*

[1]Department of Physiology, National University of Singapore, Singapore

[2]Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore

[3]Department of Pediatrics, Duke University, Durham, NC, USA

*Corresponding author

Running Title Page

a) Running title

Wnt signaling and drug resistance in cancer

b) Corresponding author

David M. Virshup

Program in Cancer and Stem Cell Biology, Duke-NUS Medical School

8 College Road, Singapore, 169857

david.virshup@duke-nus.edu.sg

c)

Number of text pages: 27

Number of tables: 3

Number of figures: 3

Number of references: 184

Number of words in *Abstract*: 167

Number of words in *Introduction*: 181

Number of words in *Discussion*: 265

d) Nonstandard abbreviations

MMTV, mouse mammary tumor virus; ER, endoplasmic reticulum; CRD, cysteine-rich domain; RSPO, R-Spondin; APC, adenomatous polyposis coli; GSK3, glycogen synthase kinase 3; CK1α, casein kinase 1 alpha; β-TrCP, beta-transducin repeats containing protein; TCF/LEF, T-cell factor/lymphoid enhancer-binding factor; ABC transporter, ATP-binding cassette transporter

Abstract

Wnts are secreted proteins that bind to cell surface receptors to activate downstream signaling cascades. Normal Wnt signaling plays key roles in embryonic development and adult tissue homeostasis. The secretion of Wnt ligands, the turnover of Wnt receptors, and the signaling transduction are tightly regulated and fine-tuned to keep the signaling output "just right". Hyperactivated Wnt signaling due to recurrent genetic alterations drives several human cancers. Elevated Wnt signaling also confers resistance to multiple conventional and targeted cancer therapies through diverse mechanisms including maintaining the cancer stem cell population, enhancing DNA damage repair, facilitating transcriptional plasticity, and promoting immune evasion. Different classes of Wnt signaling inhibitors targeting key nodes of the pathway have been developed and show efficacy in treating Wnt-driven cancers and subverting Wnt-mediated therapy resistance in preclinical studies. Several of these inhibitors have advanced to clinical trials, both singly and in combination with other existing FDA-approved anti-cancer modalities. In the near future, pharmacological inhibition of Wnt signaling may be a real choice for cancer patients.

Significance Statement

We review the latest insights in Wnt signaling, ranging from basic biology to therapeutic implications in cancer. Recent studies extend our understanding of this ancient signaling pathway and describe the development and improvement of anti-Wnt therapeutic modalities for cancer.

Introduction

Wnt signaling is an evolutionarily conserved signaling transduction pathway that plays important roles in embryonic development and adult tissue homeostasis. Dysregulated Wnt signaling causes human cancers and an increasing number of studies reveal that elevated Wnt signaling contributes to drug resistance in cancer therapy. Given the core role of Wnt signaling in multiple cancers, the Wnt pathway has been one of the hottest targets of drug development. Several Wnt pathway inhibitors have been developed and show promising efficacy in treating Wnt-driven cancers and subverting Wnt-mediated therapy resistance in preclinical studies. In this review, we will present an update on recent findings in the Wnt signaling transduction pathway and advances in pharmacological targeting of Wnt signaling. We will focus on the roles of Wnt signaling in cancer drug resistance as well as anti-Wnt signaling-based combination therapies. As multiple Wnt inhibitors are being widely used in preclinical studies and some have advanced to clinical trials, resistance to Wnt blockade is also observed in certain Wnt-dependent normal tissue and cancers. Here we will also summarize the potential mechanisms that confer resistance to Wnt inhibitors.

1. Wnt signaling pathway

1.1 Wnt genes and proteins

Wnts are secreted proteins encoded by Wnt genes that are present in all clades of metazoans (Holstein, 2012). The first mammalian Wnt gene, mouse *Int-1*, was identified in 1982 as a proto-oncogene in the mouse genome whose expression was activated by mouse mammary tumor virus (MMTV) proviral DNA integration leading to mouse mammary cancers (Nusse and Varmus, 1982). The *Int-1* gene was subsequently found to be a homolog of the *Drosophila Wingless* gene that controls segment polarity in fly larval development (Rijsewijk *et al.*, 1987). Therefore, genes of this family are called *Wnt* as a blend, or portmanteau, of *Wingless* and *Int*

(Nusse *et al.*, 1991). There are 19 Wnt genes in most mammalian genomes, including the human genome, which can be categorized into 12 subfamilies.

Wnt proteins are 350-400 amino acids in length and ~40 kDa in size. They contain 22 or 24 conserved cysteine residues that form 11 or 12 intra-molecular disulfide bonds that are important for the proper folding of the peptides into functionally active proteins (Macdonald *et al.*, 2014). Wnt proteins undergo post-translational modification after translation. Besides glycosylation, all Wnt proteins require a post-translational modification, the addition of a palmitoleate moiety on a conserved serine residue, catalyzed by a membrane bound O-acyltransferase called PORCN in the endoplasmic reticulum (ER) (Takada *et al.*, 2006; Proffitt and Virshup, 2012; Najdi *et al.*, 2012). This serine residue is conserved in all Wnts across different species except in a distantly related Wnt gene named *WntD* in Drosophila that regulates NK-κb rather than β-catenin signaling (Fig. 1A and 1B) (Ching *et al.*, 2008). The palmitoleation is necessary for the interaction of Wnts with a cargo receptor called WLS that transports Wnts from ER to the plasma membrane (Coombs *et al.*, 2010; Jia Yu *et al.*, 2014). The palmitoleic moiety is also required for direct binding sites for Wnt ligand and its receptor Frizzled on the cell membrane (Fig. 1C and 1D) (Janda *et al.*, 2012; Hirai *et al.*, 2019). Previous studies from our group has shown that all assessable human Wnts lost signaling activity when *PORCN* was knocked out, and this could be rescued by *PORCN* re-expression (Najdi *et al.*, 2012). Because of the important role of *PORCN* in Wnt signaling, mutations of the X-linked *PORCN* gene lead to embryonic lethality in males, and focal defects due to random X inactivation in surviving females (X Wang *et al.*, 2007). The O-linked palmitoleate makes Wnt proteins hydrophobic and therefore limits the biological activity of secreted Wnt proteins to a short range, unlike circulating protein hormones such as insulin that act at a distance.

1.2 Wnt receptors

As secreted but hydrophobic morphogens, Wnts travel locally to bind to cell surface receptors and co-receptors to activate downstream signaling transduction cascades. Wnts have several types of receptors. The best known are the 10 Frizzleds (Fzds) and their co-receptors LRP5/6. However, an increasing number of co-receptors such as GPR124, Reck, and TMEM59 (Cho *et al.*, 2017) (Posokhova *et al.*, 2015) (Zhou and Nathans, 2014; Vanhollebeke *et al.*, 2015) (Gerlach *et al.*, 2018), and alternative receptors including Ror and Ryk have been identified (Niehrs, 2012). The Frizzled receptors are seven-transmembrane (7TM) proteins and have N-terminal extracellular cysteine-rich domains (CRD). The crystal structure of *Xenopus* WNT8 in complex with mouse Frizzled-8 CRD reveals the multiple interacting surfaces of Wnt-Fzd binding, including a hydrophobic groove in the CRD that binds to the hydrophobic palmitoleate on Wnt (Janda *et al.*, 2012). Additional structures have extended these results, suggesting palmitoleate binding serves to dimerize Frizzled CRDs (Hirai *et al.*, 2019) (Nile and Hannoush, 2019).

The abundance of cell surface Frizzled proteins is regulated by post-translational modification. Recent studies identified two highly homologous Wnt target genes called *RNF43* and *ZNRF3*, encoding two transmembrane RING domain-containing E3 ubiquitin ligases. RNF43 and ZNRF3 can ubiquitinate the cytosolic domain of Frizzleds causing the internalization and degradation of Frizzleds. As Wnt target genes, active Wnt signaling up-regulates the expression of *RNF43* and *ZNRF3*, which in turn down-regulate the surface Wnt receptors level and the downstream Wnt signaling in a negative feedback loop (Fig. 2A and 2B) (Koo *et al.*, 2012; H-X Hao *et al.*, 2012). This RNF43/ZNRF3 mediated membrane clearance of Wnt receptors is tightly regulated by at least two processes. First, the ubiquitin-specific protease 6 (USP6) reverses the effects of RNF43/ZNRF3 by deubiquitinating Frizzleds (Fig. 2C) (Madan, Walker, *et al.*, 2016). Second, R-Spondins (RSPO1-4) are secreted protein

ligands that bind to the extracellular domains of both RNF43/ZNRF3 and LGR4/5 and lead to

their clearance from the membrane (Fig. 2D) (Niehrs, 2012; de Lau *et al.*, 2014).

1.3 The Wnt/β-catenin signaling cascade

Binding of Wnt ligands to their various receptors can activate different downstream

signaling pathways. The Wnt/β-catenin signal transduction (canonical Wnt pathway) is the

most well-studied Wnt pathway. β-catenin, encoded by the *CTNNB1* gene plays a central role

in this pathway. β-catenin is a dual function protein, involved in both cell-cell adhesion and

regulation of gene transcription. At the cell membrane, β-catenin is part of a protein complex

that forms the adherens junction, which is fundamental for the maintenance of the epithelial

cell layers. Nuclear β-catenin acts as transcriptional regulator. The abundance of β-catenin is

tightly regulated by a destruction complex that contains the scaffold protein AXIN, APC

(encoded by the well-known tumor suppressor gene *APC*, adenomatous polyposis coli), casein

kinase 1 alpha (CK1α), and glycogen synthase kinase 3 alpha and beta (GSK3α/β) (Asuni *et al.*, 2006; Doble *et al.*, 2007; Macdonald *et al.*, 2009).

In the absence of Wnt ligands (Fig. 3 left panel), β-catenin is first phosphorylated by CK1α

at Ser45, and subsequently phosphorylated by GSK3α/β at Thr41, Ser37, and Ser33 (C Liu *et al.*, 2002; Amit *et al.*, 2002). The F-box protein, β-TrCP (β-transducin repeats containing

protein) recognizes and binds to this phosphorylated β-catenin, mediating its ubiquitination by

the SCF (Skp1, Cullin, F-box) E3 ubiquitin ligase complex and subsequent proteasomal

degradation (J Jiang and Struhl, 1998; C Liu *et al.*, 1999; Hart *et al.*, 1999; Winston *et al.*, 1999).

In the presence of Wnt ligands (Fig. 3 right panel), Frizzleds and the co-receptors LRP5/6

multimerize at the cell surface. This leads to recruitment of the cytoplasmic protein Dishevelled

(DVL) to the cell membrane by interacting with cytoplasmic domains of Frizzleds (Wong *et*

al., 2003; Ma *et al.*, 2019). The Frizzled-bound Dishevelled recruits the AXIN complex through the DIX domains on Dishevelled and AXIN (Schwarz-Romond *et al.*, 2007). GSK3α/β in the AXIN complex initiates phosphorylation of the PPPSP motifs of the LRP5/6 cytoplasmic tail and primes subsequent phosphorylation by CK1s (Zeng *et al.*, 2005). As docking sites, these phosphorylated LRP5/6 PPPSP motifs recruit more AXIN complexes to the cell membrane that further phosphorylate the LRP5/6 PPPSP motifs as a positive feedback loop (Zeng *et al.*, 2008). Collectively, stimulation of Wnt ligands re-localizes the β-catenin destruction complex to the cell membrane. However, the exact mechanism by which this causes β-catenin stabilization remains controversial. Diverse models have been proposed with supporting evidence, including (i) inhibition of GSK3 activity by the phosphorylated PPPSP motif that binds to the GSK3 catalytic pocket as a "pseudo substrate" (Mi *et al.*, 2006; Cselenyi *et al.*, 2008; Piao *et al.*, 2008; G Wu *et al.*, 2009), (ii) sequestration of GSK3 from the cytoplasm into multivesicular bodies (MVBs) that restricts GSK3's access to substrates (Taelman *et al.*, 2010), (iii) dissociation of the ubiquitination machinery from the β-catenin destruction complex (VSW Li *et al.*, 2012), and (iv) degradation of AXIN and disassembly of the destruction complex (Tolwinski *et al.*, 2003). Subsequently, the newly synthesized β-catenin protein can accumulate in the cytoplasm and enter the nucleus to regulate gene transcription. Notably, inhibition of the AXIN-bound GSK3 in the Wnt signaling is independent of the well-studied AKT mediated phosphorylation on the Ser21 of GSK3α and Ser9 of GSK3β that inhibits their kinase activity (Ding *et al.*, 2000; McManus *et al.*, 2005; Ng *et al.*, 2009) And inhibition of GSK3 by Wnts also blocks degradation of other GSK3 targets including MYC (Taelman *et al.*, 2010; Madan *et al.*, 2018).

β-catenin regulates gene expression in large part in a TCF-dependent manner (Schuijers *et al.*, 2014). The TCF/LEF family is a group of DNA-bound transcription factors with cognate binding motif 5'-AGATCAAAGG-3'. They recruit Groucho family transcriptional repressors

to inhibit gene transcription in the absence of β-catenin. When Wnt is present, β-catenin is stabilized and enters the nucleus, binds to TCF, and converts TCF into a transcriptional activator. However, there is a subset of β-catenin transcriptional targets that do not require TCF/LEF factors for their regulation. In these loci, β-catenin interacts with other factors such as MyoD and FOXO to regulate gene transcription (Fig. 3 right panel) (Doumpas *et al.*, 2018).

The direct Wnt target genes are defined as genes with the conserved TCF binding sites that functionally influence gene transcription. Most Wnt target genes are cell type and developmental stage specific, indicating their promoters are subject to additional tissue-specific regulation (Nakamura *et al.*, 2016). Many of these Wnt/β-catenin targets such as MYC and cyclins regulate core biological processes such as ribosome biogenesis and cell cycle progression (Madan *et al.*, 2018). It is also interesting that a number of the more robust Wnt target genes are themselves negative regulators of Wnt signaling. These include *AXIN2*, *RNF43*, *ZNRF3*, and *NOTUM*. As described previously, RNF43/ZNRF3 negatively regulate the Frizzleds level on the cell surface (Fig. 2A and 2B) (H-X Hao *et al.*, 2012; Koo *et al.*, 2012). NOTUM is a palmitoleoyl-protein carboxylesterase that can remove the palmitoleic group on Wnt ligands (Kakugawa *et al.*, 2015). As this palmitoleic group is necessary for the interaction of Wnt ligand and receptor, Notum inactivates the function of Wnt ligands. These multiple negative feedback mechanisms guarantee that the Wnt signaling is precisely regulated and kept at the just right level.

1.4 β-catenin independent Wnt signaling pathways

β-catenin independent Wnt signaling is defined as Wnt or Frizzled initiated signaling that is independent of TCF/β-catenin mediated transcription. These 'non-canonical' Wnt signaling pathways are diverse and their role in mammals is less well understood. Some Wnts such as Wnt5a and Frizzleds are involved in the regulation of intracellular calcium levels and planar

cell polarity (Kikuchi *et al.*, 2012). Some Wnts can bind to receptor tyrosine kinases (RTK) such as ROR2 and RYK to activate downstream signaling leading to e.g. cytoneme extension (Mattes *et al.*, 2018). Notably, one established effect of Wnt5a is antagonism of the canonical Wnt/β-catenin signaling (Topol *et al.*, 2003; Ishitani *et al.*, 2003; Mikels and Nusse, 2006). The specific signaling pathway regulated by individual Wnt ligand is also based on the specific receptors existing on the cell surface, and is cell type and developmental stage dependent (Semenov *et al.*, 2007; Najdi *et al.*, 2012).

1.5 Roles of Wnt signaling in development and adult tissue

The Wnt signaling pathway is evolutionarily conserved across various species from sponges to fruit flies to human beings (Loh *et al.*, 2016). As shown by both naturally occurring and experimentally induced loss-of-function and gain-of-function mutations in many species, Wnt signaling plays important roles in both embryonic development and in maintaining adult tissue homeostasis.

The first Wnt gene, *wingless*, was identified in *Drosophila*. As the name suggests, the first mutant of *wingless* gene displayed a phenotype of transformation of wing structures into thoracic notal structures. It was also first found in *Drosophila* that Wnt is critical for the establishment of anterior-posterior polarity during embryonic segmentation (Swarup and Verheyen, 2012). In vertebrates, Wnt signaling also plays a key role in controlling body axis formation. Wnt signaling can induce secondary dorsal structures when misactivated in early *Xenopus* embryos. This axis duplication assay has been widely applied to functionally test a gene candidate's effect on the β-catenin-dependent Wnt signaling pathway. In mouse, genetic studies have shown that Wnt signaling is required for gastrulation, and Wnt3, Lrp5/6, and β-catenin knockouts generated similar phenotypes (J Wang *et al.*, 2012). In summary, Wnt

signaling controls axis patterning, cell fate specification, cell proliferation, and cell migration in embryonic development.

In the healthy adult tissue, one of the most important roles of Wnt signaling is to maintain the adult stem cells. Using lineage tracing strategies, the Wnt target gene *Lgr5* has been demonstrated to mark stem cells, first in the intestine (Barker *et al.*, 2007) and then in several other tissues including stomach, pancreas, liver, kidney, ovarian epithelium, mammary gland, hair follicle, inner ear, and taste buds (Leung *et al.*, 2018).

The intestine is one of the best studied examples of Wnt signaling and stem cell maintenance. The small intestinal epithelial layer is one of the most continuously proliferative tissues in the body and undergoes self-renewal every three to five days. It has a crypt-villus structure (Clevers, 2013). Villi are protrusions of the simple columnar epithelium that extend into the gut lumen. Crypts are invaginations of the epithelium that surround the base of each villus. One set of intestinal stem cells (also called Crypt Base Columnar cells, CBC cells) are located at the base of the crypt, surrounded by the Paneth cells. These stem cells then give rise to the Transit Amplifying cells (TA cells), which are rapidly dividing committed progenitor cells that differentiate into all the mature cell types of the epithelium. The mature differentiated cells move upward from the crypt region to the villus, and are finally shed as part of the self-renewal process of the intestinal epithelium.

As mentioned previously, the Wnt/β-catenin target gene *Lgr5* is exclusively expressed in the crypt base columnar cells, indicating active Wnt signaling in the intestinal stem cells. As a co-receptor for the RSPOs, LGR5 helps to sequester RNF43/ZNRF3 and up-regulates the cell surface Frizzled/LRP levels (Fig. 2D). This may work as a positive feedback loop to further enhance the Wnt signaling in these stem cells. There are additional diverse Wnt ligands expressed in the crypt-villus axis that may help regulate differentiation into other cell types (Gregorieff *et al.*, 2005). Paneth cells reside adjacent to the intestinal stem cells at the base of

the crypt and are known for expressing several Wnts, including *Wnt3*. Wnts secreted by Paneth cells can support the *ex vivo* organoid growth from purified intestinal epithelial cells (Sato *et al.*, 2011). However, one study from our group showed that mice lacking epithelial Wnt activity by genetic ablation of *Porcn* in the intestinal epithelium had normal intestinal homeostasis as well as normal intestinal regeneration capability after radiation injury, indicating that epithelial Wnts (including Wnts secreted by Paneth cells) are dispensable for these processes (Kabiri *et al.*, 2014). Recently, our group identified the PDGFRα⁺ pericryptal stromal cells as the critical source of Wnts and RSPO3 for the intestinal stem cells *in vivo* (Greicius *et al.*, 2018). And three other studies identified stromal cells marked by FOXL1⁺ (Aoki *et al.*, 2016; Shoshkes-Carmel *et al.*, 2018) and GLI1⁺ (Degirmenci *et al.*, 2018) respectively that form the essential Wnt-secreting niche for the stem cells in the gut. Notably, there is significant but incomplete overlap among the PDGFRα⁺, FOXL1⁺, and GLI1⁺ stromal cells (Greicius and Virshup, 2019).

Importantly, Wnt/β-catenin signaling represses proliferation of the intestinal stem cells. It is known that high Wnt/β-catenin signaling, marked by nuclear β-catenin accumulation and β-catenin target gene expression, is largely restricted to the intestinal stem cells in the crypt base, whereas the highly proliferative transit amplifying cells lack Wnt/β-catenin signaling. Instead, it is well established that the EGFR/RAS/MAPK signaling drives active proliferation in the intestine (Biteau and Jasper, 2011; Jin *et al.*, 2015). One recent study found that Wnt inhibition by PORCN inhibitor induced an initial burst of proliferation of the intestinal stem cells due to conversion of the stem cells into the transit amplifying cells with a loss of stem cell self-renewal (Kabiri *et al.*, 2018). This is driven by activation of the Wnt-suppressed MAPK signaling. And this will eventually lead to intestinal crypt ablation as the transit amplifying cells differentiate and stem cells get depleted. Collectively, these findings indicate that the role of Wnt signaling in the intestinal stem cell niche is to maintain the stemness and inhibit differentiation rather than to promote the stem cell proliferation (Greicius and Virshup, 2019).

2. Aberrant Wnt signaling in cancer and pharmacological targeting of Wnt signaling

2.1 Common alterations of Wnt pathway components in cancer

The first mammalian Wnt gene, *Int-1*, was identified because its overexpression caused mouse mammary cancer (Nusse and Varmus, 1982). The first evidence that aberrant Wnt signaling caused human cancer came from studies of hereditary colorectal cancer. In 1991, three groups independently found that the *APC* gene is mutated in the hereditary colon cancer syndrome, familiar adenomatous polyposis, as well as in many cases of the sporadic colorectal cancer (Kinzler *et al.*, 1991; Nishisho *et al.*, 1991; Groden *et al.*, 1991). Subsequent studies showed that loss-of-function mutations in the *APC* gene lead to inappropriate stabilization of β-catenin and constitutive transcriptional activation by the β-catenin/TCF complex (Rubinfeld *et al.*, 1996; Korinek *et al.*, 1997; Morin *et al.*, 1997). In agreement with the β-catenin phosphorylation/degradation model (C Liu *et al.*, 2002), point mutations in the N-terminal Ser/Thr phosphorylation sites of β-catenin that prevent its degradation were found in a subset of colorectal cancer with wildtype *APC* gene (Morin *et al.*, 1997).

Aberrant activation of Wnt/β-catenin signaling is not restricted to colorectal cancer. Similar alterations in β-catenin, APC and AXIN1 are found in liver cancer cases (La Coste *et al.*, 1998; Anastas and Moon, 2013). A growing series of activating mutations in the downstream components of the Wnt signaling pathway have also been reported in various other cancer types, including cancers originating in stomach, pancreas, ovary, endometrium, kidney, adrenal gland, biliary tract, pituitary, and soft tissues (Table 1). Researchers have also developed mouse models that confirm the tumorigenic effect of hyperactive Wnt signaling (Colnot *et al.*, 2004; Taketo and Edelmann, 2009; Koo *et al.*, 2012).

Mutations that activate Wnt/β-catenin signaling fall into two broad categories: Wnt dependent, and Wnt-independent. Mutations in *APC*, *AXIN1*, and *CTNNB1* that stabilize β-

catenin uncouple the downstream Wnt signaling from the upstream Wnt ligands, which means that β-catenin dependent transcription is constitutively activated regardless of whether the Wnt ligands and receptors are present or not. More recently, studies from several groups identified activating mutations that are Wnt dependent (Table 1). As described in the previous section, the Wnt receptors, Frizzleds and LRPs, are tightly regulated by two homolog E3 ubiquitin ligases, RNF43/ZNRF3, and Wnt agonists, RSPOs. As a negative feedback mechanism, high Wnt signaling up-regulates the expression of RNF43/ZNRF3 which leads to the membrane clearance of Wnt receptors and quenches the upstream Wnt signaling (Fig. 2A and 2B). Inactivating mutations of *RNF43* and *ZNRF3* were first reported in pancreatic and adrenocortical carcinomas respectively, and subsequently seen in cancers originating in other tissues including esophagus, stomach, biliary tract, large intestine, endometrium, and ovary (J Wu *et al.*, 2011; Giannakis *et al.*, 2014; Assié *et al.*, 2014; Madan and Virshup, 2015). Conversely, RSPOs inhibit the activity of RNF43/ZNRF3 (Fig. 2D), and gain-of-function translocations of *RSPO2* and *RSPO3* were identified first in a subset of *APC* wildtype colorectal cancer patients (Seshagiri *et al.*, 2012) and subsequently also identified in several other cancer types (Cardona *et al.*, 2014; C Li *et al.*, 2018; Picco *et al.*, 2019). Either loss of function of RNF43/ZNRF3 or gain of function of RSPO2/3 increases the surface levels of Frizzleds and LRPs and makes cells harboring these alterations highly sensitive to low levels of Wnt ligands.

In addition, DNA methylation-mediated epigenetic silencing of genes encoding secreted frizzled-related proteins (SFRPs) and Dickkopf-related proteins (DKKs) that are negative regulators of Wnt signaling are common in colorectal, breast, gastric, and ovarian cancers (Suzuki *et al.*, 2004; Caldwell *et al.*, 2004; Veeck *et al.*, 2006; 2008; Jun Yu *et al.*, 2009; Zhu *et al.*, 2012).

2.2 Targeting the Wnt pathway in cancer

Because of the core role Wnt signaling plays in several human cancers, it has been one of the hottest targets in cancer therapeutics. Multiple inhibitors targeting the Wnt pathway have been developed, and a number have advanced to clinical trials (Table 2).

Loss-of-function mutations of APC/AXIN1 or activating mutations of β-catenin represent the most common genetic alterations that constitutively activate Wnt/β-catenin signaling in human cancers (Table 1). As mentioned previously, these downstream mutations uncouple β-catenin signaling from the upstream Wnt ligand stimulation. Therefore, blocking Wnt/β-catenin signaling in these cancers requires inhibitors targeting downstream in the pathway. In many cases of colorectal cancer, the truncated APC still can functionally mediate β-catenin degradation in the AXIN-containing destruction complex, albeit with a weakened capability (Voloshanenko *et al.*, 2013). In this setting, an increase in AXIN protein can restore β-catenin degradation. This can be achieved by inhibition of tankyrases TNKS1 and TNKS2, ADP ribosyltransferases that normally drive degradation of AXIN and other proteins (Huang *et al.*, 2009; Riffell *et al.*, 2012). Several tankyrase inhibitors such as XAV939 have been developed and show significant Wnt/β-catenin signaling suppression and anticancer effect in Wnt-driven cancer with APC mutations (B Chen *et al.*, 2009; Huang *et al.*, 2009; Waaler *et al.*, 2011; 2012; James *et al.*, 2012; Lau *et al.*, 2013; Okada-Iwasaki *et al.*, 2016; Thomson *et al.*, 2017). Activation of CK1α in the destruction complex similarly causes β-catenin degradation. This was first demonstrated with pyrvinium (Thorne *et al.*, 2010) and more recently with more selective molecules (B Li *et al.*, 2017).

Another approach to inhibiting downstream β-catenin signaling is to block the interaction of β-catenin with TCF/LEF or associated transcriptional coactivators such as CBP/p300. A series of small molecule inhibitors called "inhibitor of β-catenin responsive transcription" (iCRT) inhibits the interactions between β-catenin and TCF4 and thereby suppresses the

transcriptional activity of β-catenin (Gonsalves *et al.*, 2011). The small molecule inhibitor ICG-001 binds specifically to CBP but not the related transcriptional coactivator p300, thereby disrupts the interaction of CBP with β-catenin. In preclinical studies, ICG-001 can significantly suppress β-catenin/CBP mediated transcriptional activation or repression, and shows anti-tumorigenesis effects (Emami *et al.*, 2004; Arensman *et al.*, 2014; Gang *et al.*, 2014). Its active enantiomer PRI-724 has entered early phase clinical trials for treating patients with advanced tumors (El-Khoueiry *et al.*, 2017; Ko *et al.*, 2017). Similarly, another small molecule inhibitor called Windorphen selectively targets the association of β-catenin with the transcriptional coactivator p300, but not CBP (J Hao *et al.*, 2013).

Upstream inhibitors: Hyperactive Wnt signaling in cancer can also result from elevated surface Wnt receptor abundance due to alterations in RNF43/ZNRF3 or RSPOs. To suppress Wnt signaling in such cases, studies have focused on the upstream components of the Wnt pathway that include Wnt ligand secretion, Wnt receptor turnover, and Wnt ligand-receptor interactions. As described previously, mammalian Wnts require palmitoleation by PORCN to be secreted. Therefore, small molecule inhibitors targeting PORCN can block secretion of all Wnts and thereby suppress the downstream signaling. Notably, PORCN inhibitors can shut down both canonical and non-canonical Wnt signaling. Several PORCN inhibitors have been developed. They showed potent suppressive effect in pre-clinical models of Wnt-addicted cancers (Proffitt *et al.*, 2013; X Jiang *et al.*, 2013; J Liu *et al.*, 2013; Madan, Ke, *et al.*, 2016; Bhamra *et al.*, 2017; C Li *et al.*, 2018) and have entered clinical trials. In addition, neutralizing antibodies targeting Wnt receptors (Frizzleds and LRPs) and agonists (RSPOs) and soluble Fzd-based decoy receptor of Wnt ligands have been developed by different groups. Some of these have also entered clinical trials (Ettenberg *et al.*, 2010; Gurney *et al.*, 2012; Madan and Virshup, 2015; Chartier *et al.*, 2016; Steinhart *et al.*, 2017) (Jimeno *et al.*, 2017).

3. Wnt signaling mediated resistance in cancer therapy

3.1 Wnt signaling in cancer stem cell

Stem cells are defined as multipotent cells that can perpetuate themselves through self-renewal and can also differentiate into mature cells of a particular tissue type. They are present in many adult tissues and organs and help to maintain the normal tissue architecture (Reya *et al.*, 2001). Over the past two decades, more and more studies have revealed the heterogeneity within a tumor population in various cancer types. The cancer stem cell model is one way to explain the intra-tumor heterogeneity (Visvader and Lindeman, 2008). Similar to normal stem cells, cancer stem cells refer to a subset of tumor cells that undergo self-renewal while generating differentiated cells that comprise the bulk of the tumor. However, compared to the normal tissue stem cells, cancer stem cells proliferate and differentiate aberrantly. Many studies have shown that cancer stem cells are more resistant to traditional chemotherapy and radiotherapy, which could be because of the higher expression of anti-apoptotic proteins such as MYC, multidrug resistance genes such as the ATP-binding cassette (ABC) transporters including MDR1 and MRP1, and more efficient DNA damage repair. Therefore, in many cancers, while chemotherapy or radiotherapy can kill a majority of the proliferating cells leading to tumor shrinkage, the cancer stem cells can survive and lead to cancer relapse. Cancer stem cells were also reported to contribute to tumor metastasis.

Wnt signaling is well-known for regulating stemness in many normal tissues. Several studies have shown that Wnt signaling also plays important roles in maintaining cancer stem cells in various cancer types.

CD34$^+$ bulge stem cells maintain follicular homeostasis in mouse skin. In a mouse cutaneous tumor model induced by chemical carcinogens (DMBA/TPA), CD34$^+$ cells are significantly enriched by 9-fold in the tumor tissues compared with the normal skin. And the CD34$^+$ tumor cells are 100-fold more potent in initiating tumors than unsorted tumor cells in

the limiting-dilution transplantation assay, which means this CD34[+] population contains the cancer stem cells of this mouse tumor model. It was further shown that Wnt/β-catenin signaling is essential in sustaining the CD34[+] cancer stem cell phenotype, and that β-catenin deletion leads to the loss of CD34[+] cancer stem cells as well as complete tumor regression (Malanchi *et al.*, 2008).

In pancreatic cancer, a small population of cancer cells with high intrinsic Wnt/β-catenin signaling showed properties indicative of cancer stem cells, including higher tumor-initiating capacity and drug resistance, whereas cancer cells with low Wnt activity expressed markers of differentiation. In these tumors RSPO2 was shown to enhance Wnt/β-catenin signaling to confer stemness traits to susceptible pancreatic cancer cells (Ilmer *et al.*, 2015).

In mouse and human lung adenocarcinomas, two distinct cell subpopulations were identified, one with high Wnt/β-catenin signaling and the other forming the niche that provides the Wnt ligands. The Wnt responding cells expressed the stem cell marker LGR5 and had increased tumor propagation capacity. They comprised a small minority of the tumor, but could give rise to the other cell populations of the tumor bulk. The evidence suggests that these cancer cells with active Wnt signaling have features of normal tissue stem cells. Genetic and pharmacological perturbation of Wnt signaling in this model significantly suppressed tumor progression (Tammela *et al.*, 2017).

In colorectal cancer, even though most of the cancer cases have elevated Wnt/β-catenin signaling due to mutations/alterations in the Wnt pathway components, the Wnt signaling level reflected by β-catenin localization and target genes expression is still very heterogeneous within the tumor. It is reported that high Wnt signaling functionally designates the cancer stem cells in colorectal cancer. These Wnt high tumor cells are located close to stromal myofibroblasts and respond to the myofibroblast-secreted factors to activate β-catenin-dependent transcriptions. Notably, myofibroblast-secreted factors can also restore the cancer

stem cell phenotype in more differentiated tumor cells, suggesting that the dynamic stemness in colorectal cancer is not just defined by high Wnt signaling, instead is also orchestrated by the tumor microenvironment (Vermeulen *et al.*, 2010).

Recent studies also revealed the involvement of non-coding RNAs in regulating stemness of cancer cells. Many of the reported non-coding RNAs confer stemness traits to cancer cells through activating Wnt/β-catenin signaling (Zhan *et al.*, 2017). microRNA-146a represses Numb and stabilizes β-catenin to maintain the symmetric division of colorectal cancer stem cells (Hwang *et al.*, 2014). In liver cancer stem cells, the long non-coding RNA lncTCF7 is highly expressed and triggers TCF7 expression by recruiting the SWI/SNF complex to *TCF7* promoter, thereby activating Wnt signaling. lncTCF7 is required for the self-renewal and tumorigenic capacity of liver cancer stem cells (Y Wang *et al.*, 2015). miR-142 promotes mRNA degradation of APC to activate Wnt signaling in breast cancer stem cells (Isobe *et al.*, 2014), while miR-582-3p targets mRNAs of Wnt signaling negative regulators *AXIN2*, *DKK3*, and *SRP1* for degradation to maintain stemness features in non-small cell lung cancer (Fang *et al.*, 2015).

3.2 Wnt signaling mediated resistance to conventional chemotherapy and radiotherapy

Conventional chemotherapy exposes cancer patients to cytotoxic agents to block proliferation and lead to cell death of rapidly proliferating cells including but not limited to cancer cells. Radiotherapy applies ionizing radiation to tumor tissues which damages the DNA of cancer cells and leads to cell death. Cancer stem cells are known to be more resistant to traditional chemotherapeutic agents and radiation compared to the non-stem cell populations of the tumor bulk, and thereby may be able to cause cancer relapse after chemotherapy or radiotherapy. It has been discussed in the previous section that Wnt signaling is important in

maintaining the cancer stem cells, therefore contributing to therapeutic resistance in several cancer types.

However, the protective effect conferred by Wnt signaling against chemotherapy and radiotherapy is not restricted to cancer stem cells, but also applies to the non-stem cancer cell populations. It has been reported in many cancers that the Wnt/β-catenin activity level positively correlates with the resistance to several common chemotherapeutic drugs and radiation. Chemotherapy or radiation can up-regulate Wnt signaling, and up-regulation of Wnt signaling protects cancer cells from cell cycle arrest or apoptosis. While this protective effect has been attributed to the downstream effectors of Wnt/β-catenin signaling such as survivin in one study, more generally the underlining mechanism still remains unclear (Watson *et al.*, 2010; Gao *et al.*, 2013; Nagano *et al.*, 2013; Emons *et al.*, 2017). Two recent studies found that elevated Wnt signaling enhanced the DNA damage repair and thereby conferred resistance to the PARP inhibitor olaparib in ovarian cancers (Fukumoto *et al.*, 2019; Yamamoto *et al.*, 2019). This mechanism could also protect cancer cells from DNA damage caused by other conventional chemo agents or radiation. Another study reported that canonical Wnt signaling is activated in therapy-induced senescence of cancer cells and can enhance the tumor initiation capacity of cancer cells released or escaping from senescence (Milanovic *et al.*, 2017). In addition, blockade of Wnt signaling by small molecular inhibitors or antibodies targeting Frizzleds or RSPOs can significantly enhance the toxicity of chemotherapy or radiotherapy, or re-sensitize the resistant tumors to the treatment in many studies. Notably, except for those Wnt-driven tumors, anti-Wnt signaling treatment itself normally does not show potent suppressive effect on tumor growth, but can significantly enhance the therapeutic effects of conventional chemotherapeutic agents in combinational treatment, further suggesting that Wnt signaling has a specific role in mediating resistance to chemotherapy (Nagaraj *et al.*, 2015;

Chartier *et al.*, 2016; Trillsch *et al.*, 2017; Fischer, Yeung, *et al.*, 2017; Fischer, Cancilla, *et al.*, 2017).

3.3 Wnt signaling mediated resistance to targeted therapy

Wnt signaling also confers resistance against more targeted therapies. Prostate cancer is hormone sensitive, therefore most prostate cancer patients who cannot be cured by surgery or radiation undergo androgen deprivation therapy. However, the majority of those patients eventually develop lethal metastatic castration-resistant prostate cancer. Some of the resistance is due to intracrine biosynthesis of androgens, which can be blocked by abiraterone acetate/prednisone (AA/P). But there are still many patients who fail to respond to AA/P. A recent clinical study showed that the AA/P nonresponders have more alterations of Wnt pathway components in their tumors resulting in elevated Wnt/β-catenin signaling. Organoids derived from tumors of the nonresponders are also resistant to AA/P, but can be re-sensitized to AA/P by Wnt pathway inhibition (Dehm *et al.*, 2018). This finding is consistent with preclinical study results that Wnt/β-catenin signaling can be activated in prostate cancer cells after androgen-deprivation to promote androgen-independent growth, and combining antiandrogen agent with a Wnt pathway inhibitor can achieve enhanced growth suppression effect in both androgen-dependent and -independent prostate cancer cells (G Wang *et al.*, 2008; Lee *et al.*, 2015). In addition to the canonical Wnt/β-catenin signaling, it is also reported that the non-canonical Wnt signaling is activated by WNT5A and WNT7B in the circulating tumor cells which mediates resistance to the androgen receptor inhibitor (Miyamoto *et al.*, 2015). Finally, both canonical and non-canonical Wnt signaling are involved in the bone metastases that are common in prostate cancer (Dai *et al.*, 2008; Nandana *et al.*, 2017).

Active Wnt signaling also contributes to resistance to growth factor signaling pathway inhibitors. High nuclear β-catenin level is associated with resistance to PI3K/AKT/mTOR

inhibitors in colorectal cancer patients (Arqués *et al.*, 2016). Mechanistically, inhibition of PI3K/AKT signaling promotes nuclear accumulation of the proapoptotic tumor suppressor FOXO3a. However, high nuclear β-catenin confers resistance to the FOXO3a-mediated apoptosis and subverts FOXO3a to promote metastasis in colon cancer, which can be reversed by tankyrase inhibition (Tenbaum *et al.*, 2012; Arqués *et al.*, 2016). In preclinical studies, elevated Wnt signaling has been observed in PI3K inhibitor treated breast cancer cells and BRAF inhibitor treated colorectal cancer cells. PI3K inhibition promotes the expression of Wnt ligands in breast cancers, while BRAF inhibition up-regulates β-catenin signaling through activating the focal adhesion kinase (FAK) in colorectal cancer. Blocking Wnt/β-catenin signaling by tankyrase inhibitor or PORCN inhibitor can significantly enhance the tumor suppression effect of these small molecular inhibitors targeting the growth factor signaling pathways (Tzeng *et al.*, 2015; Solzak *et al.*, 2017; Solberg *et al.*, 2018; G Chen *et al.*, 2018). In EGFR mutated lung cancer, even though EGFR inhibitors are not observed to significantly up-regulate Wnt signaling in preclinical studies, Wnt/β-catenin signaling has been shown to drive resistance to EGFR inhibitors in lung cancer cells, as tankyrase inhibitor and EGFR inhibitor in combination can synergistically suppress lung cancer cell growth *in vitro* and *in vivo* (Casás-Selves *et al.*, 2012; Scarborough *et al.*, 2017).

Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies that entered clinical trials for treating acute myeloid leukemia. Two independent studies found that Wnt/β-catenin signaling promotes primary and acquired resistance to BET inhibition in leukemia (Fong *et al.*, 2015; Rathert *et al.*, 2015). Mechanistically, BET inhibitors disrupt the BRD4-chromatin interaction and repress BRD4-dependent transcription of genes such as *MYC* to suppress cancer progression. However, in the presence of BET inhibitor, β-catenin binds to the promoter regions that are originally occupied by BRD4, and maintains the expression levels of key target genes including *MYC*. This evidence establishes Wnt/β-catenin

signaling as a major driver and candidate biomarker of resistance to BET inhibitors in a subpopulation of leukemia cells that show high transcriptional plasticity.

Recently, two independent studies revealed that Wnt signaling mediates resistance to complete response to Hedgehog signaling inhibition in basal cell carcinoma (BCC) (Biehs *et al.*, 2018; Sánchez-Danés *et al.*, 2018). BCC is the most common malignancy in humans and typically arises due to constitutively activation of Hedgehog signaling. Treatment with Hedgehog signaling inhibitor vismodegib mediates differentiation of BCC cells from a hair follicle stem cell like phenotype to an interfollicular epidermis or isthmus cell fate, and thereby leads to tumor regression (Sánchez-Danés *et al.*, 2018). However, BCC tumors always relapse after vismodegib withdrawal (Tang *et al.*, 2016). It was found that a small population of LGR5+ BCC cells with active Wnt signaling escape from vismodegib-induced differentiation and mediate tumor relapse after treatment discontinuation. Importantly, combining vismodegib with PORCN inhibitor led to the eradication of persistent BCC cells and prevented tumor relapse in mouse models.

3.4 Wnt signaling mediated resistance to immunotherapy

The roles of Wnt signaling in regulating normal hematopoiesis remains a controversial topic (Staal *et al.*, 2008; Kabiri *et al.*, 2015). However, increasing evidence from recent studies suggests that Wnt/β-catenin signaling drives the primary, adaptive, and acquired resistance to cancer immunotherapy, first in the anti-CTLA-4/PD-1/PD-L1 treatment of melanoma but in other settings as well (Luke *et al.*, 2019). In human metastatic melanoma samples, activation of Wnt/β-catenin signaling correlates with the absence of a T-cell gene expression signature which reflects a lack of T-cell infiltration. Activation of tumor intrinsic β-catenin signaling suppresses the expression of tumor-cell-intrinsic chemokines such as CCL4, thereby suppresses the recruitment of CD103[+] dendritic cells and subsequent activation of CD8[+] T-

cells (Spranger *et al.*, 2015). The melanoma derived WNT5A can also activate β-catenin signaling in the dendritic cells in a paracrine mode, which up-regulates the expression and activity of the indoleamine 2,3-dioxygenase-1 (IDO) enzyme in local dendritic cells. This promotes the development of tolerogenic dendritic cells and drives the differentiation of regulatory T-cells (Holtzhausen *et al.*, 2015; Zhao *et al.*, 2018). Concurrent inhibition of Wnt/β-catenin signaling enhanced the effect of immune checkpoint inhibitors in select preclinical models.

3.5 Anti-Wnt signaling based combination cancer therapies

As discussed previously, Wnt signaling mediates resistance to several therapeutic modalities in clinical practice as well as multiple anti-cancer agents developed in preclinical studies. Therefore, several drug combination studies combining Wnt signaling inhibitors with other conventional cytotoxic agents or targeted inhibitors have been tested in preclinical studies and showed improved efficacy. Some of them have advanced into clinical trials. Moreover, recent technical advances in genome sequencing and genetic screening identified a group of genetically defined cancers that are addicted to Wnt signaling and other oncogenic pathways, such as a subset of colon cancers that harbor concurrent mutations in *BRAF* and *RNF43* or *RSPOs* (Yan *et al.*, 2017) and *RNF43*-mutant pancreatic cancers that show high dependency on PI3K/mTOR signaling (Zhong *et al.*, 2019). These findings inspired the development of PORCN inhibitor and growth factor pathway inhibitor combinational treatment in preclinical studies and clinical trials. Here, we summarize the drug combinations with Wnt pathway inhibitors for cancer therapy in both preclinical studies and clinical trials (Table 3).

4. Resistance to Wnt pathway blockade in normal tissue and Wnt-driven cancer

As discussed previously, dysregulated Wnt signaling is the driver of a series genetically defined cancers, and elevated Wnt signaling can mediate resistance to various therapeutic strategies. Therefore, targeting Wnt signaling pathway has been attracting attention in the field of cancer research for a long time. Researchers have developed different strategies to block Wnt signaling, including antibodies targeting receptors or agonists, PORCN inhibitors, tankyrase inhibitors, etc. These strategies may apply to different cases based on the specific alterations in the Wnt pathway. However, since Wnt signaling also maintains the homeostasis of normal tissue including bone, taste buds, and hair and gut stem cells, one common concern in using Wnt pathway inhibitors is the potential adverse effect on normal tissues with high dependency on Wnt signaling such as the gastrointestinal tract. Indeed, tankyrase inhibitors have been shown to cause severe toxicity to the gut as well as loss of body weight in mice when used for cancer treatment, which limits the use of tankyrase inhibitors in human patients (Lau *et al.*, 2013). However, surprisingly, PORCN inhibitors can be well tolerated by mice at therapeutic doses for cancer but showing no significant side effect on gut (Proffitt *et al.*, 2013; J Liu *et al.*, 2013; Madan, Ke, *et al.*, 2016). In cancers, even those driven by *RNF43* mutations can develop resistance to Wnt blockade, as two pancreatic cancer cell lines with the same *RNF43* loss-of-function mutation show different sensitivity to PORCN inhibitor. Interestingly, they were isolated from the same metastasis of the same patient, but one cell line is sensitive while the other is resistant to PORCN inhibitor (X Jiang *et al.*, 2013). In colorectal cancers with *APC* mutations, some cell lines are sensitive to tankyrase inhibitors while others are resistant, even though the expression of Wnt target genes can also be repressed by tankyrase inhibitors in the resistant cell lines (Lau *et al.*, 2013). This observation reveals that there are potential mechanisms that mediates resistance to Wnt pathway inhibitors in normal tissues and cancers. Three mechanisms are described here to explain the resistance.

4.1 ABC transporters

ATP-binding cassette transporters (ABC transporters) are members of a transport system superfamily. The ABC transporters consist of two ATP-binding domains and two transmembrane domains. These four domains can present in one peptide as a protein, or two peptides that form a dimer. The two transmembrane domains typically contains twelve α-helices that form a pore-like structure across the membrane. The ATP-binding domains that have ATPase activity utilize the energy of ATP binding and hydrolysis to drive the conformational change of the transmembrane domains, thereby energize the translocation of substrates across the membrane. There are many members in the ABC transporter family that are responsible for uptake or export of various substrates for the cell (Glavinas *et al.*, 2004).

ABC transporters are known to cause the multidrug resistance (MDR) phenotype in cancer cells by pumping diverse anticancer drugs out of the cell. ABCB1 is the most extensively-studied ABC transporter related to drug efflux, and is also called MDR1 (Robey *et al.*, 2018). Many studies have shown that the expression of ABC transporters is up-regulated when tumor cells get resistant to certain drug and this always results in multidrug resistance. So far, there is no direct evidence to show that resistance to Wnt pathway inhibitors is because of ABC transporters. However, one recent study from our group shows that in the mouse intestine, the stroma cells that supply Wnts and RSPOs and form the niche for the intestinal stem cells express a subset of ABC transporters, and are therefore resistant to various xenobiotics including PORCN inhibitors (Chee *et al.*, 2018). This property of the intestinal stroma cells could be due to the unpredictable environment rich in various xenobiotics in the gastrointestinal tract. But it can well explain the differential toxicities that tankyrase inhibitors and PORCN inhibitors have on the gut, as tankyrase inhibitors target the Wnt responding cells (the stem cells) directly, while PORCN inhibitors target the Wnt suppling cells, the resistant stroma cells

here. This finding provides the rationale for the safety of the gut when using PORCN inhibitors in cancer therapy.

4.2 Further mutations of Wnt pathway components

It is generally accepted that upstream Wnt pathway inhibitors such as PORCN inhibitors are less effective in cancer cells with mutations of downstream Wnt pathway components such as *APC* mutations, even though it is also reported that Wnt ligands are required to maintain the high levels of Wnt signaling in colorectal cancer cells with *APC* mutations (Voloshanenko *et al.*, 2013). Besides, it has been observed in many cancer types that inactivating mutations of *RNF43/ZNRF3*, *RSPOs* translocation, activating mutations of β-catenin, and loss of *APC* are almost mutually exclusive, which reflects a rule in tumorigenesis that Wnt/β-catenin signaling only need to be activated in one way or another. However, co-occurrence of mutations in both upstream and downstream Wnt pathway does exist in some rare cases, in which the PORCN inhibitors may not work even though alterations of *RNF43/ZNRF3* or *RSPOs* can be detected. In addition, mutations in downstream components of the Wnt pathway can happen during the long-term treatment with upstream Wnt pathway inhibitors. These resistant clones may be selected by the treatment and become the dominant population of the tumor. This process has been reported in a colorectal cancer cell line VACO6. VACO6 harbors a RSPO3 translocation and is sensitive to the PORCN inhibitor LGK974. However, these cells developed resistance to LGK974 within three months when cultured with a sublethal concentration of LGK974. Exome sequencing of the resistant VACO6 clone found truncating mutations in AXIN1 that are absent in the parental cell line (Picco *et al.*, 2017). Interestingly, these truncating mutations have been reported in the COSMIC database as cancer-related somatic variants. This study demonstrates that further mutations in downstream components of Wnt signaling can confer

secondary resistance to genetically defined cancers that are sensitive to upstream Wnt pathway blockade.

4.3 Activation of other compensatory signaling pathways

Wnt signaling can mediate resistance to inhibitors of other signaling pathways especially the growth factor signaling pathways, and so it is not surprising that activation of these growth factor signaling pathways can compensate for Wnt pathway blockade. For example, mTOR signaling is reported to mediate resistance to tankyrase inhibitors in colorectal cancer (Mashima *et al.*, 2017). Mechanistically, most of the pro-oncogenic and anti-oncogenic targets are regulated by more than one pathway. For example, c-Myc, as a Wnt signaling effector, is regulated at the transcriptional level and posttranslational level by Wnt signaling, as well as PI3K/AKT/mTOR signaling, MAPK signaling, etc. Therefore, inhibiting one signaling input can be compensated by other regulators, and may have a minimal effect on the output. Notably, in many Wnt-driven cancers, the growth factor signaling pathways are also hyperactivated due to mutations in *EGFR*, *KRAS*, *BRAF*, *PI3K*, *PTEN*, etc. Therefore, developing combination drug therapy is a promising solution to maximize the therapeutic effects.

Concluding remarks

Since the discovery of the first mammalian *Wnt* gene and its function in the mouse mammary cancer nearly four decades ago, the Wnt signaling pathway has been extensively investigated worldwide. While these studies comprehensively revealed the molecular mechanisms and functional effects of the Wnt signaling in normal and diseases, numerous questions still remain to be answered. Recent findings in the Wnt field continue to extend our understanding of this evolutionarily conserved ancient signaling pathway. As a highlight of this review, an increasing number of studies reveal and confirm the key roles of Wnt signaling in cancer initiation, progression, and drug resistance, inspiring pharmacological targeting of Wnt signaling in patients.

Importantly, increasing knowledge in the Wnt field have facilitated the development of multiple Wnt pathway inhibitors along with rational drug combination strategies. These inhibitors and drug combinations showed promising efficacy in carefully selected preclinical cancer models, and some have advanced to clinical trials. However, considering the important roles of Wnt signaling in maintaining normal tissue homeostasis, the on-target adverse effects of Wnt pathway inhibitors cannot be neglected. Notably, while those upstream Wnt pathway inhibitors including PORCN inhibitors and the anti-Frizzleds antibody advanced to clinical trials and showed manageable side effects, several of the downstream inhibitors such as the tankyrase inhibitors have remained at the preclinical stage, possibly due to the toxicity to the gastrointestinal tract. Therefore, it will be important to both develop more selective inhibitors that have minimal toxicity on normal tissue, and also develop synergistic drug combinations so that lower dosages can be used to improve both the therapeutic index and the anticancer efficacy.

Acknowledgements

We acknowledge Sivakumar Parthiban for assistance with the consensus modeling of Wnt

proteins. Z. Zhong acknowledges Prof. Shazib Pervaiz for the supervision on his PhD training.

We thank all members of the Virshup lab for useful discussions on this work and apologize to

our colleagues whose work could not be cited here due to space limitation.

Authorship Contributions

Performed data analysis: Z. Zhong and D.M. Virshup

Wrote or contributed to the writing of the manuscript: Z. Zhong and D.M. Virshup

Footnotes

This study is supported in part by the National Research Foundation Singapore and administered by the Singapore Ministry of Health's National Medical Research Council under the Singapore Translational Research (STaR) Award Program to D.M. Virshup. Z. Zhong was supported by the National University of Singapore (NUS) Research Scholarship. D.M. Virshup has a financial interest in ETC-159.

References

Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, Ben-Neriah Y, and Alkalay I (2002) Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. *Genes Dev* **16**:1066–1076, Cold Spring Harbor Lab.

Anastas JN, and Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. *Nat Rev Cancer*.

Aoki R, Shoshkes-Carmel M, Gao N, Shin S, May CL, Golson ML, Zahm AM, Ray M, Wiser CL, Wright CVE, and Kaestner KH (2016) Foxl1-expressing mesenchymal cells constitute the intestinal stem cell niche. *Cell Mol Gastroenterol Hepatol* **2**:175–188, Elsevier.

Arensman MD, Telesca D, Lay AR, Kershaw KM, Wu N, Donahue TR, and Dawson DW (2014) The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth. *Mol Cancer Ther* **13**:2303–2314.

Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, and Palmer HG (2016) Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. *Clin Cancer Res* **22**:644–656.

Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libé R, de Reyniès A, and Bertherat J (2014) Integrated genomic characterization of adrenocortical carcinoma. *Nat Genet* **46**:607–612.

Asuni AA, Hooper C, Reynolds CH, Lovestone S, Anderton BH, and Killick R (2006) GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. *Eur J Neurosci* **24**:3387–3392, John Wiley & Sons, Ltd (10.1111).

Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, and Clevers H (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* **449**:1003–1007.

Bhamra I, Adams N, Armer R, Bingham M, McKeever H, Phillips C, Ben Thompson, and Woodcock S (2017) Novel porcupine (PORCN) inhibitor RXC004: Evaluation in models of RNF43 loss of function cancers. *Journal of Clinical Oncology* **35**:e14094–e14094, American Society of Clinical Oncology.

Biehs B, Dijkgraaf GJP, Piskol R, Alicke B, Boumahdi S, Peale F, Gould SE, and de Sauvage FJ (2018) A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition. *Nature* **562**:429–433.

Biteau B, and Jasper H (2011) EGF signaling regulates the proliferation of intestinal stem cells in Drosophila. *Development* **138**:1045–1055, Oxford University Press for The Company of Biologists Limited.

Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM, and Morton DG (2004) The Wnt antagonist sFRP1 in colorectal tumorigenesis. *Cancer Res* **64**:883–888.

Cardona GM, Bell K, Portale J, Gaffney D, Moy C, Platero S, Lorenzi MV, and Karkera J (2014) Abstract 2408: Identification of R-Spondin fusions in various types of human cancer. *Cancer Res* **74**:2408–2408, American Association for Cancer Research.

Casás-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA, Chan DC, Tan AC, and DeGregori J (2012) Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. *Cancer Res* **72**:4154–4164.

Chartier C, Raval J, Axelrod F, Bond C, Cain J, Dee-Hoskins C, Ma S, Fischer MM, Shah J, Wei J, Ji M, Lam A, Stroud M, Yen W-C, Yeung P, Cancilla B, O'Young G, Wang M, Kapoun AM, Lewicki J, Hoey T, and Gurney A (2016) Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types. *Cancer Res* **76**:713–723.

Chee YC, Pahnke J, Bunte R, Adsool VA, Madan B, and Virshup DM (2018) Intrinsic Xenobiotic Resistance of the Intestinal Stem Cell Niche. *Dev Cell* **46**:681–695.e5.

Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan C-W, Wei S, Hao W, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C, and Lum L (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. *Nat Chem Biol* **5**:100–107.

Chen G, Gao C, Gao X, Zhang DH, Kuan S-F, Burns TF, and Hu J (2018) Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer. *Mol Cancer Ther* **17**:806–813.

Ching W, Hang HC, and Nusse R (2008) Lipid-independent secretion of a Drosophila Wnt protein. *J Biol Chem* **283**:17092–17098, American Society for Biochemistry and Molecular Biology.

Cho C, Smallwood PM, and Nathans J (2017) Reck and Gpr124 Are Essential Receptor Cofactors for Wnt7a/Wnt7b-Specific Signaling in Mammalian CNS Angiogenesis and Blood-Brain Barrier Regulation. *Neuron* **95**:1056–1073.e5.

Clevers H (2013) The intestinal crypt, a prototype stem cell compartment. *Cell* **154**:274–284.

Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, Giovannini M, and Perret C (2004) Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. *PNAS* **101**:17216–17221.

Coombs GS, Yu J, Canning CA, Veltri CA, Covey TM, Cheong JK, Utomo V, Banerjee N, Zhang ZH, Jadulco RC, Concepcion GP, Bugni TS, Harper MK, Mihalek I, Jones CM, Ireland CM, and Virshup DM (2010) WLS-dependent secretion of WNT3A requires Ser209 acylation and vacuolar acidification. *J Cell Sci* **123**:3357–3367.

Cselenyi CS, Jernigan KK, Tahinci E, Thorne CA, Lee LA, and Lee E (2008) LRP6 transduces a canonical Wnt signal independently of Axin degradation by inhibiting GSK3's phosphorylation of beta-catenin. *PNAS* **105**:8032–8037, National Academy of Sciences.

Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, and Keller ET (2008) Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. *Cancer Res* **68**:5785–5794.

de Lau W, Peng WC, Gros P, and Clevers H (2014) The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength. *Genes Dev* **28**:305–316.

Degirmenci B, Valenta T, Dimitrieva S, Hausmann G, and Basler K (2018) GLI1-expressing mesenchymal cells form the essential Wnt-secreting niche for colon stem cells. *Nature* **558**:449–453.

Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, and Kohli M (2018) A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. *Ann Oncol* **29**:352–360.

Ding VW, Chen RH, and McCormick F (2000) Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. *J Biol Chem* **275**:32475–32481, American Society for Biochemistry and Molecular Biology.

Doble BW, Patel S, Wood GA, Kockeritz LK, and Woodgett JR (2007) Functional Redundancy of GSK-3α and GSK-3β in Wnt/β-Catenin Signaling Shown by Using an Allelic Series of Embryonic Stem Cell Lines. *Dev Cell* **12**:957–971, Elsevier.

Doumpas N, Lampart F, Robinson MD, Lentini A, Nestor CE, Cantù C, and Basler K (2018) TCF/LEF dependent and independent transcriptional regulation of Wnt/β-catenin target genes. *The EMBO Journal* e98873.

El-Khoueiry AB, Ning Y, Yang D, Cole S, Kahn M, Zoghbi M, Berg J, Fujimori M, Inada T, Kouji H, and Lenz HJ (2017) A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. *Journal of Clinical Oncology*, American Society of Clinical Oncology.

Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo J-L, Oh SW, Kim HY, Moon SH, Ha JR, and Kahn M (2004) A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. *PNAS* **101**:12682–12687.

Emons G, Spitzner M, Reineke S, Möller J, Auslander N, Kramer F, Hu Y, Beissbarth T, Wolff HA, Rave-Fränk M, Hessmann E, Gaedcke J, Ghadimi BM, Johnsen SA, Ried T, and Grade M (2017) Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling. *Mol Cancer Res* **15**:1481–1490.

Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, Schuller AG, Yuan J, Ospina B, Green J, Yu Q, Walsh R, Li S, Schmitz R, Heine H, Bilic S, Ostrom L, Mosher R, Hartlepp KF, Zhu Z, Fawell S, Yao Y-M, Stover D, Finan PM, Porter JA, Sellers WR, Klagge IM, and Cong F (2010) Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. *PNAS* **107**:15473–15478.

Fang L, Cai J, Chen B, Wu S, Li R, Xu X, Yang Y, Guan H, Zhu X, Zhang L, Yuan J, Wu J, and Li M (2015) Aberrantly expressed miR-582-3p maintains lung cancer stem cell-like traits by activating Wnt/β-catenin signalling. *Nature Communications* **6**:8640.

Fischer MM, Cancilla B, Yeung VP, Cattaruzza F, Chartier C, Murriel CL, Cain J, Tam R, Cheng C-Y, Evans JW, O'Young G, Song X, Lewicki J, Kapoun AM, Gurney A, Yen W-C, and Hoey T (2017) WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. *Sci Adv* **3**:e1700090.

Fischer MM, Yeung VP, Cattaruzza F, Hussein R, Yen W-C, Murriel C, Evans JW, O'Young G, Brunner AL, Wang M, Cain J, Cancilla B, Kapoun A, and Hoey T (2017) RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations. *Sci Rep* **7**:15270.

Fong CY, Gilan O, Lam EYN, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, Giotopoulos G, Lugo D, Jeffrey P, Lee SC-W, Carpenter C, Gregory R, Ramsay RG, Lane SW, Abdel-Wahab O, Kouzarides T, Johnstone RW, Dawson S-J, Huntly BJP, Prinjha RK, Papenfuss AT, and Dawson MA (2015) BET inhibitor resistance emerges from leukaemia stem cells. *Nature* **525**:538–542.

Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, and Zhang R (2019) N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance. *Cancer Res* **79**:2812–2820.

Gang EJ, Hsieh Y-T, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway EM, Pelus LM, Crispino J, Mullighan CG, McMillan M, Müschen M, Kahn M, and Kim Y-M (2014) Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. *Oncogene* **33**:2169–2178.

Gao Y, Liu Z, Zhang X, He J, Pan Y, Hao F, Xie L, Li Q, Qiu X, and Wang E (2013) Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells. *Cancer Letters* **336**:231–239.

Gerlach JP, Jordens I, Tauriello DVF, van 't Land-Kuper I, Bugter JM, Noordstra I, van der Kooij J, Low TY, Pimentel-Muiños FX, Xanthakis D, Fenderico N, Rabouille C, Heck AJR, Egan DA, and Maurice MM (2018) TMEM59 potentiates Wnt signaling by promoting signalosome formation. *PNAS* **115**:E3996–E4005, National Academy of Sciences.

Giannakis M, Hodis E, Jasmine Mu X, Yamauchi M, Rosenbluh J, Cibulskis K, Saksena G, Lawrence MS, Qian ZR, Nishihara R, Van Allen EM, Hahn WC, Gabriel SB, Lander ES, Getz G, Ogino S, Fuchs CS, and Garraway LA (2014) RNF43 is frequently mutated in colorectal and endometrial cancers. *Nat Genet* **46**:1264–1266.

Glavinas H, Krajcsi P, Cserepes J, and Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. *Curr Drug Deliv* **1**:27–42.

Gonsalves FC, Klein K, Carson BB, Katz S, Ekas LA, Evans S, Nagourney R, Cardozo T, Brown AMC, and DasGupta R (2011) An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. *PNAS* **108**:5954–5963.

Gregorieff A, Pinto D, Begthel H, Destree O, Kielman M, and Clevers H (2005) Expression pattern of Wnt signaling components in the adult intestine. *Gastroenterology* **129**:626–638.

Greicius G, and Virshup DM (2019) Stromal control of intestinal development and the stem cell niche. *Differentiation*, doi: 10.1016/j.diff.2019.01.001, Elsevier.

Greicius G, Kabiri Z, Sigmundsson K, Liang C, Bunte R, Singh MK, and Virshup DM (2018) PDGFRα+ pericryptal stromal cells are the critical source of Wnts and RSPO3 for murine intestinal stem cells in vivo. *PNAS* **545**:201713510.

Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, and Robertson M (1991) Identification and characterization of the familial adenomatous polyposis coli gene. *Cell* **66**:589–600.

Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, Ma S, Mitra S, Park I-K, Pickell K, Sato A, Satyal S, Stroud M, Tran H, Yen W-C, Lewicki J, and Hoey T (2012) Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. *PNAS* **109**:11717–11722.

Hao H-X, Xie Y, Zhang Y, Charlat O, Oster E, Avello M, Lei H, Mickanin C, Liu D, Ruffner H, Mao X, Ma Q, Zamponi R, Bouwmeester T, Finan PM, Kirschner MW, Porter JA, Serluca FC, and Cong F (2012) ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. *Nature* **485**:195–200.

Hao J, Ao A, Zhou L, Murphy CK, Frist AY, Keel JJ, Thorne CA, Kim K, Lee E, and Hong CC (2013) Selective Small Molecule Targeting β-Catenin Function Discovered by In Vivo Chemical Genetic Screen. *Cell Rep* **4**:898–904.

Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, Perret C, Rubinfeld B, Margottin F, Benarous R, and Polakis P (1999) The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. *Curr Biol* **9**:207–210.

Hirai H, Matoba K, Mihara E, Arimori T, and Takagi J (2019) Crystal structure of a mammalian Wnt-frizzled complex. *Nature Structural & Molecular Biology 2013 20:9* **26**:372–379.

Holstein TW (2012) The evolution of the Wnt pathway. *Cold Spring Harb Perspect Biol* **4**:a007922–a007922.

Holtzhausen A, Zhao F, Evans KS, Tsutsui M, Orabona C, Tyler DS, and Hanks BA (2015) Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and

Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. *Cancer Immunol Res* **3**:1082–1095.

Huang S-MA, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Porter JA, Bauer A, and Cong F (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. *Nature* **461**:614–620.

Hwang W-L, Jiang J-K, Yang S-H, Huang T-S, Lan H-Y, Teng H-W, Yang C-Y, Tsai Y-P, Lin C-H, Wang H-W, and Yang M-H (2014) MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. *Nat Cell Biol* **16**:268–280.

Ilmer M, Boiles AR, Regel I, Yokoi K, Michalski CW, Wistuba II, Rodriguez J, Alt E, and Vykoukal J (2015) RSPO2 Enhances Canonical Wnt Signaling to Confer Stemness-Associated Traits to Susceptible Pancreatic Cancer Cells. *Cancer Res* **75**:1883–1896.

Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M, Shibuya H, Moon RT, Ninomiya-Tsuji J, and Matsumoto K (2003) The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. *Mol Cell Biol* **23**:131–139, American Society for Microbiology.

Isobe T, Hisamori S, Hogan DJ, Zabala M, Hendrickson DG, Dalerba P, Cai S, Scheeren F, Kuo AH, Sikandar SS, Lam JS, Qian D, Dirbas FM, Somlo G, Lao K, Brown PO, Clarke MF, and Shimono Y (2014) miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. *eLife Sciences* **3**:3983.

James RG, Davidson KC, Bosch KA, Biechele TL, Robin NC, Taylor RJ, Major MB, Camp ND, Fowler K, Martins TJ, and Moon RT (2012) WIKI4, a novel inhibitor of tankyrase and Wnt/ß-catenin signaling. *PLoS ONE* **7**:e50457.

Janda CY, Waghray D, Levin AM, Thomas C, and Garcia KC (2012) Structural basis of Wnt recognition by Frizzled. *Science* **337**:59–64.

Jiang J, and Struhl G (1998) Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb. *Nature* **391**:493–496, Nature Publishing Group.

Jiang X, Hao H-X, Growney JD, Woolfenden S, Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, Smith TR, Avello M, Charlat O, Xie Y, Porter JA, Pan S, Liu J, McLaughlin ME, and Cong F (2013) Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. *PNAS* **110**:12649–12654.

Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, Brachmann RK, and Smith DC (2017) A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. *Clin Cancer Res* **23**:7490–7497, American Association for Cancer Research.

Jin Y, Ha N, Forés M, Xiang J, Gläßer C, Maldera J, Jiménez G, and Edgar BA (2015) EGFR/Ras Signaling Controls Drosophila Intestinal Stem Cell Proliferation via Capicua-Regulated Genes. *PLOS Genet* **11**:e1005634, Public Library of Science.

Kabiri Z, Greicius G, Madan B, Biechele S, Zhong Z, Zaribafzadeh H, Edison, Aliyev J, Wu Y, Bunte R, Williams BO, Rossant J, and Virshup DM (2014) Stroma provides an intestinal stem cell niche in the absence of epithelial Wnts. *Development* **141**:2206–2215.

Kabiri Z, Greicius G, Zaribafzadeh H, Hemmerich A, Counter CM, and Virshup DM (2018) Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells. *J Clin Invest* **128**, American Society for Clinical Investigation.

Kabiri Z, Numata A, Kawasaki A, Edison, Tenen DG, and Virshup DM (2015) Wnts are dispensable for differentiation and self-renewal of adult murine hematopoietic stem cells. *Blood* **126**:1086–1094.

Kakugawa S, Langton PF, Zebisch M, Howell S, Chang T-H, Liu Y, Feizi T, Bineva G, O'Reilly N, Snijders AP, Jones EY, and Vincent J-P (2015) Notum deacylates Wnt proteins to suppress signalling activity. *Nature* **519**:187–192, Nature Publishing Group.

Kikuchi A, Yamamoto H, Sato A, and Matsumoto S (2012) Wnt5a: its signalling, functions and implication in diseases. *Acta Physiol (Oxf)* **204**:17–33.

Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, and Markham A (1991) Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. *Science* **251**:1366–1370.

Ko AH, Chiorean EG, Kwak EL, Lenz HJ, Nadler PI, Wood DL, Fujimori M, Inada T, Kouji H, and McWilliams RR (2017) Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. *Journal of Clinical Oncology*, American Society of Clinical Oncology.

Koo B-K, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, van Es JH, Mohammed S, Heck AJR, Maurice MM, and Clevers H (2012) Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. *Nature* **488**:665–669.

Korinek V, Barker N, Morin PJ, Van Wichen D, de Weger R, Kinzler KW, Vogelstein B, and Clevers H (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. *Science* **275**:1784–1787.

La Coste de A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, and Perret C (1998) Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. *PNAS* **95**:8847–8851.

Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, Magnuson S, Sambrone A, Schutten M, Firestein R, Machon O, Korinek V, Choo E, Diaz D, Merchant M, Polakis P, Holsworth DD, Krauss S, and Costa M (2013) A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. *Cancer Res* **73**:3132–3144.

Lee E, Ha S, and Logan SK (2015) Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. *PLoS ONE* **10**:e0141589–16.

Leung C, Tan SH, and Barker N (2018) Recent Advances in Lgr5+ Stem Cell Research. *Trends in Cell Biology* **28**:380–391.

Li B, Orton D, Neitzel LR, Astudillo L, Shen C, Long J, Chen X, Kirkbride KC, Doundoulakis T, Guerra ML, Zaias J, Fei DL, Rodriguez-Blanco J, Thorne C, Wang Z, Jin K, Nguyen DM, Sands LR, Marchetti F, Abreu MT, Cobb MH, Capobianco AJ, Lee E, and Robbins DJ (2017) Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors. *Sci Signal* **10**:eaak9916.

Li C, Cao J, Zhang N, Tu M, Xu F, Wei S, Chen X, and Xu Y (2018) Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor. *Sci Rep* **8**:14244.

Li VSW, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, Mohammed S, Heck AJR, Maurice MM, Mahmoudi T, and Clevers H (2012) Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. *Cell* **149**:1245–1256.

Liu C, Kato Y, Zhang Z, Do VM, Yankner BA, and He X (1999) beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. *PNAS* **96**:6273–6278, National Academy of Sciences.

Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, and He X (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. *Cell* **108**:837–847.

Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo G, Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarroel MC, Schultz PG, Wu X, McNamara P, Sellers WR, Petruzzelli L, Boral AL, Seidel HM, McLaughlin ME, Che J, Carey TE, Vanasse G, and Harris JL (2013) Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. *PNAS* **110**:20224–20229.

Loh KM, van Amerongen R, and Nusse R (2016) Generating Cellular Diversity and Spatial Form: Wnt Signaling and the Evolution of Multicellular Animals. *Dev Cell* **38**:643–655.

Luke JJ, Bao R, Sweis RF, Spranger S, and Gajewski TF (2019) WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. *Clin Cancer Res* clincanres.1942.2018.

Ma W, Chen M, Kang H, Steinhart Z, Angers S, He X, and Kirschner MW (2019) Single molecule dynamics of Dishevelled at the plasma membrane and Wnt pathway activation. *bioRxiv* **70**:624882, Cold Spring Harbor Laboratory.

Macdonald BT, Hien A, Zhang X, Iranloye O, Virshup DM, Waterman ML, and He X (2014) Disulfide bond requirements for active Wnt ligands. *J Biol Chem* **289**:18122–18136.

Macdonald BT, Tamai K, and He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. *Dev Cell* **17**:9–26.

Madan B, and Virshup DM (2015) Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs. *Mol Cancer Ther* **14**:1087–1094.

Madan B, Harmston N, Nallan G, Montoya A, Faull P, Petretto E, and Virshup DM (2018) Temporal dynamics of Wnt-dependent transcriptome reveal an oncogenic Wnt/MYC/ribosome axis. *J Clin Invest* **128**:5620–5633.

Madan B, Ke Z, Harmston N, Ho SY, Frois AO, Alam J, Jeyaraj DA, Pendharkar V, Ghosh K, Virshup IH, Manoharan V, Ong EHQ, Sangthongpitag K, Hill J, Petretto E, Keller TH, Lee MA, Matter A, and Virshup DM (2016) Wnt addiction of genetically defined cancers reversed by PORCN inhibition. *Oncogene* **35**:2197–2207.

Madan B, Walker MP, Young R, Quick L, Orgel KA, Ryan M, Gupta P, Henrich IC, Ferrer M, Marine S, Roberts BS, Arthur WT, Berndt JD, Oliveira AM, Moon RT, Virshup DM, Chou MM, and Major MB (2016) USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds. *PNAS* **113**:E2945–54.

Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, and Huelsken J (2008) Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. *Nature* **452**:650–653.

Mashima T, Taneda Y, Jang M-K, Mizutani A, Muramatsu Y, Yoshida H, Sato A, Tanaka N, Sugimoto Y, and Seimiya H (2017) mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. *Oncotarget* **8**:47902–47915.

Mattes B, Dang Y, Greicius G, Kaufmann LT, Prunsche B, Rosenbauer J, Stegmaier J, Mikut R, Özbek S, Nienhaus GU, Schug A, Virshup DM, and Scholpp S (2018) Wnt/PCP controls spreading of Wnt/β-catenin signals by cytonemes in vertebrates. *eLife Sciences* **7**:180.

McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, and Alessi DR (2005) Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. *The EMBO Journal* **24**:1571–1583, EMBO Press.

Mi K, Dolan PJ, and Johnson GVW (2006) The low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activity. *J Biol Chem* **281**:4787–4794, American Society for Biochemistry and Molecular Biology.

Mikels AJ, and Nusse R (2006) Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. *PLOS Biol* **4**:e115, Public Library of Science.

Milanovic M, Fan DNY, Belenki D, Däbritz JHM, Zhao Z, Yu Y, Dörr JR, Dimitrova L, Lenze D, Monteiro Barbosa IA, Mendoza-Parra MA, Kanashova T, Metzner M, Pardon K, Reimann M, Trumpp A, Dörken B, Zuber J, Gronemeyer H, Hummel M, Dittmar G, Lee S, and Schmitt CA (2017) Senescence-associated reprogramming promotes cancer stemness. *Nature* **15**:482.

Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu C-L, Shioda T, Ramaswamy S, Ting DT, Toner M, Maheswaran S, and Haber DA (2015) RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. *Science* **349**:1351–1356.

Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, and Kinzler KW (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. *Science* **275**:1787–1790.

Nagano H, Tomimaru Y, Eguchi H, Hama N, Wada H, Kawamoto K, Kobayashi S, Mori M, and Doki Y (2013) MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells. *International Journal of Oncology* **43**:1066–1072.

Nagaraj AB, Joseph P, Kovalenko O, Singh S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S, and DiFeo A (2015) Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance. *Oncotarget* **6**:23720–23734.

Najdi R, Proffitt K, Sprowl S, Kaur S, Yu J, Covey TM, Virshup DM, and Waterman ML (2012) A uniform human Wnt expression library reveals a shared secretory pathway and unique signaling activities. *Differentiation* **84**:203–213.

Nakamura Y, de Paiva Alves E, Veenstra GJC, and Hoppler S (2016) Tissue- and stage-specific Wnt target gene expression is controlled subsequent to β-catenin recruitment to cis-regulatory modules. *Development* **143**:1914–1925, Oxford University Press for The Company of Biologists Limited.

Nandana S, Tripathi M, Duan P, Chu C-Y, Mishra R, Liu C, Jin R, Yamashita H, Zayzafoon M, Bhowmick NA, Zhau HE, Matusik RJ, and Chung LWK (2017) Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis. *Cancer Res* **77**:1331–1344.

Ng SS, Mahmoudi T, Danenberg E, Bejaoui I, de Lau W, Korswagen HC, Schutte M, and Clevers H (2009) Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade. *J Biol Chem* **284**:35308–35313, American Society for Biochemistry and Molecular Biology.

Niehrs C (2012) The complex world of WNT receptor signalling. *Nat Rev Mol Cell Biol* **13**:767–779, Nature Publishing Group.

Nile AH, and Hannoush RN (2019) Fatty acid recognition in the Frizzled receptor family. *J Biol Chem* **294**:726–736, American Society for Biochemistry and Molecular Biology.

Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S, and Hedge P (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. *Science* **253**:665–669.

Nusse R, and Varmus HE (1982) Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. *Cell* **31**:99–109.

Nusse R, Brown A, Papkoff J, Scambler P, Shackleford G, McMahon A, Moon R, and Varmus H (1991) A new nomenclature for int-1 and related genes: the Wnt gene family. *Cell* **64**:231.

Okada-Iwasaki R, Takahashi Y, Watanabe Y, Ishida H, Saito J-I, Nakai R, and Asai A (2016) The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase. *Mol Cancer Ther* **15**:1525–1534.

Piao S, Lee S-H, Kim H, Yum S, Stamos JL, Xu Y, Lee S-J, Lee J, Oh S, Han J-K, Park B-J, Weis WI, and Ha N-C (2008) Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta-catenin signaling. *PLoS ONE* **3**:e4046, Public Library of Science.

Picco G, Chen ED, Alonso LG, Behan FM, Gonçalves E, Bignell G, Matchan A, Fu B, Banerjee R, Anderson E, Butler A, Benes CH, McDermott U, Dow D, Iorio F, Stronach E, Yang F, Yusa K, Saez-Rodriguez J, and Garnett MJ (2019) Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening. *Nature Communications* **10**:2198, Nature Publishing Group.

Picco G, Petti C, Centonze A, Torchiaro E, Crisafulli G, Novara L, Acquaviva A, Bardelli A, and Medico E (2017) Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions. *EMBO Molecular Medicine* **9**:293–303.

Posokhova E, Shukla A, Seaman S, Volate S, Hilton MB, Wu B, Morris H, Swing DA, Zhou M, Zudaire E, Rubin JS, and St Croix B (2015) GPR124 functions as a WNT7-specific coactivator of canonical β-catenin signaling. *Cell Rep* **10**:123–130.

Proffitt KD, and Virshup DM (2012) Precise regulation of porcupine activity is required for physiological Wnt signaling. *J Biol Chem* **287**:34167–34178.

Proffitt KD, Madan B, Ke Z, Pendharkar V, Ding L, Lee MA, Hannoush RN, and Virshup DM (2013) Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. *Cancer Res* **73**:502–507.

Rathert P, Roth M, Neumann T, Muerdter F, Roe J-S, Muhar M, Deswal S, Cerny-Reiterer S, Peter B, Jude J, Hoffmann T, Boryń ŁM, Axelsson E, Schweifer N, Tontsch-Grunt U, Dow LE, Gianni D, Pearson M, Valent P, Stark A, Kraut N, Vakoc CR, and Zuber J (2015) Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. *Nature* **525**:543–547.

Reya T, Morrison SJ, Clarke MF, and Weissman IL (2001) Stem cells, cancer, and cancer stem cells. *Nature* **414**:105–111.

Riffell JL, Lord CJ, and Ashworth A (2012) Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. *Nature Reviews Drug Discovery 2014 13:7* **11**:923–936.

Rijsewijk F, Schuermann M, Wagenaar E, Parren P, Weigel D, and Nusse R (1987) The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. *Cell* **50**:649–657.

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, and Gottesman MM (2018) Revisiting the role of ABC transporters in multidrug-resistant cancer. *Nat Rev Cancer* **56**:85.

Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, and Polakis P (1996) Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. *Science* **272**:1023–1026.

Sato T, van Es JH, Snippert HJ, Stange DE, Vries RG, van den Born M, Barker N, Shroyer NF, van de Wetering M, and Clevers H (2011) Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. *Nature* **469**:415–418.

Sánchez-Danés A, Larsimont J-C, Liagre M, Muñoz-Couselo E, Lapouge G, Brisebarre A, Dubois C, Suppa M, Sukumaran V, del Marmol V, Tabernero J, and Blanpain C (2018) A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. *Nature* **562**:434–438.

Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, and DeGregori J (2017) AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. *Clin Cancer Res* **23**:1531–1541.

Schuijers J, Mokry M, Hatzis P, Cuppen E, and Clevers H (2014) Wnt-induced transcriptional activation is exclusively mediated by TCF/LEF. *The EMBO Journal* **33**:146–156, EMBO Press.

Schwarz-Romond T, Fiedler M, Shibata N, Butler PJG, Kikuchi A, Higuchi Y, and Bienz M (2007) The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. *Nature Structural & Molecular Biology 2013 20:9* **14**:484–492, Nature Publishing Group.

Semenov MV, Habas R, Macdonald BT, and He X (2007) SnapShot: Noncanonical Wnt Signaling Pathways. *Cell* **131**:1378–1378.e2.

Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, Guillory J, Ha C, Dijkgraaf GJP, Stinson J, Gnad F, Huntley MA, Degenhardt JD, Haverty PM, Bourgon R, Wang W, Koeppen H, Gentleman R, Starr TK, Zhang Z, Largaespada DA, Wu TD, and de Sauvage FJ (2012) Recurrent R-spondin fusions in colon cancer. *Nature* **488**:660–664.

Shoshkes-Carmel M, Wang YJ, Wangensteen KJ, Tóth B, Kondo A, Massasa EE, Itzkovitz S, and Kaestner KH (2018) Subepithelial telocytes are an important source of Wnts that supports intestinal crypts. *Nature* **557**:242–246.

Solberg NT, Waaler J, Lund K, Mygland L, Olsen PA, and Krauss S (2018) TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer. *Mol Cancer Res* **16**:543–553.

Solzak JP, Atale RV, Hancock BA, Sinn AL, Pollok KE, Jones DR, and Radovich M (2017) Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. *NPJ Breast Cancer* **3**:17.

Spranger S, Bao R, and Gajewski TF (2015) Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. *Nature* **523**:231–235.

Staal FJT, Luis TC, and Tiemessen MM (2008) WNT signalling in the immune system: WNT is spreading its wings. *Nat Rev Immunol* **8**:581–593.

Steinhart Z, Pavlovic Z, Chandrashekhar M, Hart T, Wang X, Zhang X, Robitaille M, Brown KR, Jaksani S, Overmeer R, Boj SF, Adams J, Pan J, Clevers H, Sidhu S, Moffat J, and Angers S (2017) Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. *Nat Med* **23**:60–68.

Suzuki H, Watkins DN, Jair K-W, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, and Baylin SB (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. *Nat Genet* **36**:417–422.

Swarup S, and Verheyen EM (2012) Wnt/Wingless signaling in Drosophila. *Cold Spring Harb Perspect Biol* **4**:a007930–a007930.

Taelman VF, Dobrowolski R, Plouhinec J-L, Fuentealba LC, Vorwald PP, Gumper I, Sabatini DD, and De Robertis EM (2010) Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. *Cell* **143**:1136–1148.

Takada R, Satomi Y, Kurata T, Ueno N, Norioka S, Kondoh H, Takao T, and Takada S (2006) Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. *Dev Cell* **11**:791–801.

Taketo MM, and Edelmann W (2009) Mouse models of colon cancer. *Gastroenterology* **136**:780–798.

Tammela T, Sánchez-Rivera FJ, Cetinbas NM, Wu K, Joshi NS, Helenius K, Park Y, Azimi R, Kerper NR, Wesselhoeft RA, Gu X, Schmidt L, Cornwall-Brady M, Yilmaz ÖH, Xue W, Katajisto P, Bhutkar A, and Jacks T (2017) A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. *Nature* **545**:355–359.

Tang JY, Ally MS, Chanana AM, Mackay-Wiggan JM, Aszterbaum M, Lindgren JA, Ulerio G, Rezaee MR, Gildengorin G, Marji J, Clark C, Bickers DR, and Epstein EH (2016) Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet Oncology* **17**:1720–1731.

Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramón y Cajal S, Schwartz S, Vivancos A, Espín E, Rojas S, Baselga J, Tabernero J, Muñoz A, and Palmer HG (2012) β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. *Nat Med* **18**:892–901.

Thomson DW, Wagner AJ, Bantscheff M, Benson RE, Dittus L, Duempelfeld B, Drewes G, Krause J, Moore JT, Mueller K, Poeckel D, Rau C, Salzer E, Shewchuk L, Hopf C, Emery JG, and Muelbaier M (2017) Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines. *J Med Chem* **60**:5455–5471.

Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, Jernigan KK, Meyers KC, Hang BI, Waterson AG, Kim K, Melancon B, Ghidu VP, Sulikowski GA, LaFleur B, Salic A, Lee LA, Miller DM, and Lee E (2010) Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. *Nat Chem Biol* **6**:829–836.

Tolwinski NS, Wehrli M, Rives A, Erdeniz N, DiNardo S, and Wieschaus E (2003) Wg/Wnt signal can be transmitted through arrow/LRP5,6 and Axin independently of Zw3/Gsk3beta activity. *Dev Cell* **4**:407–418.

Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, and Yang Y (2003) Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. *J Cell Biol* **162**:899–908, Rockefeller University Press.

Trillsch F, Preinfalk V, Rahmeh M, Vogel M, Czogalla B, Burges A, Jeschke U, and Mahner S (2017) Inhibition of Wnt signaling as therapeutic option in platinum-resistant ovarian cancer. *Journal of Clinical Oncology*, doi: 10.1200/JCO.2017.35.15_suppl.e17050, American Society of Clinical Oncology.

Tzeng H-E, Yang L, Chen K, Wang Y, Liu Y-R, Pan S-L, Gaur S, Hu S, and Yen Y (2015) The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. *Oncotarget* **6**:11061–11073.

Vanhollebeke B, Stone OA, Bostaille N, Cho C, Zhou Y, Maquet E, Gauquier A, Cabochette P, Fukuhara S, Mochizuki N, Nathans J, and Stainier DY (2015) Tip cell-specific requirement for an atypical Gpr124- and Reck-dependent Wnt/β-catenin pathway during brain angiogenesis. *eLife Sciences* **4**:2807, eLife Sciences Publications Limited.

Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Dürst M, Kristiansen G, Huszka C, Knüchel R, and Dahl E (2006) Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. *Oncogene* **25**:3479–3488, Nature Publishing Group.

Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knüchel R, and Dahl E (2008) Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. *Mol Cancer* **7**:83–19, BioMed Central.

Vermeulen L, de Sousa e Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G, and Medema JP (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. *Nat Cell Biol* **12**:468–476.

Visvader JE, and Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat Rev Cancer* **8**:755–768.

Voloshanenko O, Erdmann G, Dubash TD, Augustin I, Metzig M, Moffa G, Hundsrucker C, Kerr G, Sandmann T, Anchang B, Demir K, Boehm C, Leible S, Ball CR, Glimm H, Spang R, and Boutros M (2013) Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. *Nature Communications* **4**:2610.

Waaler J, Machon O, Kries von JP, Wilson SR, Lundenes E, Wedlich D, Gradl D, Paulsen JE, Machonova O, Dembinski JL, Dinh H, and Krauss S (2011) Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. *Cancer Res* **71**:197–205, American Association for Cancer Research.

Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova O, Gradl D, Voronkov A, Kries von JP, and Krauss S (2012) A

novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. *Cancer Res* **72**:2822–2832.

Wang G, Wang J, and Sadar MD (2008) Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. *Cancer Res* **68**:9918–9927.

Wang J, Sinha T, and Wynshaw-Boris A (2012) Wnt signaling in mammalian development: lessons from mouse genetics. *Cold Spring Harb Perspect Biol* **4**:a007963–a007963.

Wang X, Reid Sutton V, Omar Peraza-Llanes J, Yu Z, Rosetta R, Kou Y-C, Eble TN, Patel A, Thaller C, Fang P, and Van den Veyver IB (2007) Mutations in X-linked PORCN, a putative regulator of Wnt signaling, cause focal dermal hypoplasia. *Nat Genet* **39**:836–838, Nature Publishing Group.

Wang Y, He L, Du Y, Zhu P, Huang G, Luo J, Yan X, Ye B, Li C, Xia P, Zhang G, Tian Y, Chen R, and Fan Z (2015) The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. *Cell Stem Cell* **16**:413–425.

Watson RL, Spalding AC, Zielske SP, Morgan M, Kim AC, Bommer GT, Eldar-Finkelman H, Giordano T, Fearon ER, Hammer GD, Lawrence TS, and Ben-Josef E (2010) GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. *Neoplasia* **12**:357–365.

Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, and Harper JW (1999) The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. *Genes Dev* **13**:270–283, Cold Spring Harbor Lab.

Wong H-C, Bourdelas A, Krauss A, Lee H-J, Shao Y, Wu D, Mlodzik M, Shi D-L, and Zheng J (2003) Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. *Mol Cell* **12**:1251–1260.

Wu G, Huang H, Garcia Abreu J, and He X (2009) Inhibition of GSK3 phosphorylation of beta-catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6. *PLoS ONE* **4**:e4926, Public Library of Science.

Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay V, Klimstra DS, Offerhaus GJA, Klein AP, Kopelovich L, Carter H, Karchin R, Allen PJ, Schmidt CM, Naito Y, Diaz LA, Kinzler KW, Papadopoulos N, Hruban RH, and Vogelstein B (2011) Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. *PNAS* **108**:21188–21193.

Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan G-L, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, and Bitler BG (2019) Activation of Wnt signaling promotes olaparib resistant ovarian cancer. *Mol Carcinog* **68**:7.

Yan HHN, Lai JCW, Ho SL, Leung WK, Law WL, Lee JFY, Chan AKW, Tsui WY, Chan ASY, Lee BCH, Yue SSK, Man AHY, Clevers H, Yuen ST, and Leung SY (2017)

RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. *Gut* **66**:1645–1656.

Yu Jia, Chia J, Canning CA, Jones CM, Bard FA, and Virshup DM (2014) WLS retrograde transport to the endoplasmic reticulum during Wnt secretion. *Dev Cell* **29**:277–291.

Yu Jun, Tao Q, Cheng YY, Lee KY, Ng SSM, Cheung KF, Tian L, Rha SY, Neumann U, Röcken C, Ebert MPA, Chan FKL, and Sung JJY (2009) Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. *Cancer* **115**:49–60, John Wiley & Sons, Ltd.

Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C, Almeida K, Wang J, Doble B, Woodgett J, Wynshaw-Boris A, Hsieh J-C, and He X (2008) Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. *Development* **135**:367–375, The Company of Biologists Ltd.

Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, and He X (2005) A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. *Nature* **438**:873–877.

Zhan T, Rindtorff N, and Boutros M (2017) Wnt signaling in cancer. *Oncogene* **36**:1461–1473.

Zhao F, Xiao C, Evans KS, Theivanthiran T, DeVito N, Holtzhausen A, Liu J, Liu X, Boczkowski D, Nair S, Locasale JW, and Hanks BA (2018) Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization. *Immunity* **48**:147–160.e7.

Zhong Z, Sepramaniam S, Chew XH, Wood K, Lee MA, Madan B, and Virshup DM (2019) PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. *Oncogene* **67**:7.

Zhou Y, and Nathans J (2014) Gpr124 controls CNS angiogenesis and blood-brain barrier integrity by promoting ligand-specific canonical wnt signaling. *Dev Cell* **31**:248–256.

Zhu J, Zhang S, Gu L, and Di W (2012) Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma. *Carcinogenesis* **33**:2334–2343.

Figure Legends

Figure 1. Wnts are secreted proteins with conserved domains and residues.

(A) The consensus modeling of 19 human Wnts. The amino acid sequences of 19 human Wnts were aligned, and the amino acid conservation scores were calculated using The ConSurf Server website (http://consurf.tau.ac.il). The conservation scores were then mapped on the human Wnt3 crystal structure (PDB 6AHY chain B).

(B) The consensus modeling of Wnt homologues. The palmitoleation site and Frizzled interaction sites are conserved in all Wnts. 2635 amino acid sequences that are homologues of human Wnt3 were collected from UNIREF90 using HMMER algorithm. The conservation scores were calculated from 150 amino acid sequences representative of the 2635 sequences using The ConSurf Server website and mapped on the human Wnt3 crystal structure.

(C) The crystal structure of human Wnt3 in complex with mouse Frizzled 8 CRD (PDB 6AHY).

(D) The Wnt secretion pathway. Wnts are palmitoleated by PORCN in the endoplasmic reticulum. The palmitoleic moiety (red line) facilitates the interaction of Wnts with the cargo receptor WLS that transports Wnts to the plasma membrane. Multiple routes of Wnt release and extracellular transport including diffusion, exovesicles, and cytoneme-mediated transport have been proposed.

Figure 2. The abundance of cell surface Wnt receptors is tightly regulated by RNF43/ZNRF3, USP6, and R-Spondins.

(A) *RNF43* and *ZNRF3* are Wnt/β-catenin target genes.

(B) RNF43 and ZNRF3 ubiquitinate the cytosolic domain of Frizzleds causing the internalization and degradation of Frizzleds.

(C) USP6 reverses the effects of RNF43/ZNRF3 by deubiquitinating Frizzleds.

(D) R-Spondins bind to the extracellular domains of both RNF43/ZNRF3 and LGR4/5 leading to their membrane clearance.

Figure 3. The canonical Wnt/β-catenin signaling cascade.

(Left panel) In the absence of Wnt ligands, β-catenin is phosphorylated, ubiquitinated, and degraded by the β-catenin destruction complex. (Right panel) Binding of Wnt ligands to the receptors re-localizes the destruction complex to the membrane and interferes with its activity. Subsequently, newly synthesized β-catenin accumulates in the cytoplasm and enters the nucleus to regulate gene transcription. Refer to the text for detailed description.

Table 1. Common genetic alterations of Wnt pathway components in human cancers

Gene	Type of mutation	Primary tissues	% mutated	Reference
APC	Mainly frameshift and nonsense mutations that lead to truncated APC proteins with compromised ability to degrade β-catenin; LOH (loss of heterozygosity)	Large intestine	70%	a
		Stomach	13%	a
		Endometrium	7%	a
		Liver	2.7%	a
AXIN1	Mainly missense mutations, truncating mutations, and deep deletions	Liver	7%	a
		Stomach	3%	a
		Large intestine	2.5%	a
CTNNB1	Mainly missense mutations in the N-terminal Ser/Thr phosphorylation sites of β-catenin that prevent its degradation	Liver	29%	a
		Endometrium	18%	a
		Adrenal cortex	16%	a
		Large intestine	6%	a
		Stomach	6%	a
		Pancreas	2.7%	a
RNF43	Mainly missense mutations and truncating mutations due to frameshift or nonsense mutations, LOH, and homozygous deletion	Ovary (mucinous carcinoma/ mucinous borderline tumor)	21% / 9%	(Ryland et al., 2013)
		Stomach	13%	a
		Biliary tract (liver fluke-associated cholangiocarcinoma)	9.3%	(Ong et al., 2012)
		Large intestine	9%	a
		Pancreas	7%	a
		Endometrium	4%	a

ZNRF3	Mainly missense mutations and truncating mutations due to frameshift or nonsense mutations, LOH, and homozygous deletion	Adrenal cortex	20%	[a]
		Large intestine	4%	[a]
		Stomach	2.1%	[a]
RSPO2	Chromosome rearrangement leading to the recurrent *EIF3E-RSPO2* gene fusions	Large intestine	2.9%	(Seshagiri et al., 2012)
		Others (lung, head & neck, esophagus, stomach, ovary, and breast)	1-2%	(Cardona et al., 2014; Li et al., 2018)
RSPO3	Chromosome rearrangement leading to the recurrent *PTPRK-RSPO3* gene fusions	Large intestine	7.4%	(Seshagiri et al., 2012)
		Others (lung, head & neck, esophagus, ovary, and breast)	1-11%	(Cardona et al., 2014)

[a] Curated from the cBioPortal database (https://www.cbioportal.org) in July 2019.

Table 2. Inhibitors of the Wnt signaling and their effects in cancer

Targets and functions	Agent name	Functional effects in cancer	Development stage	Reference
Small molecule **tankyrase (TNKS1/2)** inhibitors, stabilizing AXIN1/2	IWRs		Discovery	(Chen et al., 2009)
	XAV939	Inhibited colony formation of colorectal cancer cell line DLD-1.		(Huang et al., 2009)
	WIKI4			(James et al., 2012)
	NVP-TNKS656			(Shultz et al., 2013)
	JW67, JW74	Both compounds suppressed *in vitro* proliferation of colorectal cancer cell line SW480; JW74 reduced SW480 *in vivo* tumor growth and adenoma formation in Apc_{Min} mice.	Preclinical	(Waaler et al., 2011)
	JW55	Suppressed *in vitro* proliferation of SW480; Decreased adenoma formation in conditional *Apc* knockout mice.		(Waaler et al., 2012)
	G007-LK	Suppressed *in vitro* colony formation and *in vivo* tumor growth of colorectal cancer cell lines COLO-320DM and SW403 and spheroid formation of Apc_{Min} mouse intestinal adenoma.		(Lau et al., 2013)
	K-756	Suppressed *in vitro* proliferation of COLO-320DM and SW403; Showed dose-dependent inhibition of Wnt signaling in DLD-1 xenografts.		(Okada-Iwasaki et al., 2016)
Small molecule **CK1α** activators, promoting β-catenin degradation	Pyrvinium	Suppressed *in vitro* proliferation of colorectal cancer cell lines SW480, DLD-1, SW620, HCT116, and HT29; Reduced adenoma formation in Apc_{Min} mice.	Preclinical	(Thorne et al., 2010; Li et al., 2014)
	SSTC3	Suppressed intestinal organoid formation from Apc_{Min} mice and *Apc* knockout mice; Reduced adenoma formation in Apc_{Min} mice; Suppressed *in vitro* colony formation of HT29, SW403, and HCT116 and *in vivo* tumor growth of HCT116;		(Li et al., 2017)

		Suppressed tumor organoid formation from three patient colorectal tumors and *in vivo* growth of xenografts.		
Small molecule inhibitors blocking **β-catenin/TCF** interaction	iCRT3, iCRT5, and iCRT14	iCRTs led to cell cycle arrest in HCT116 and HT29; iCRT3 suppressed *in vitro* growth of primary human colon cancer specimens; iCRT14 reduced HCT116 and HT29 xenograft growth.	Preclinical	(Gonsalves et al., 2011)
Small molecule inhibitors blocking **β-catenin/CBP** interaction	ICG-001	Suppressed *in vitro* growth and led to apoptosis in SW480 and HCT116; Suppressed *in vivo* growth of SW620 xenografts; Reduced adenoma formation in *Apc*Min mice; Suppressed *in vitro* growth of pancreatic cancer cell lines AsPC-1, L3.6pl, MIA PaCa-2, and PANC-1; Improved survival of AsPC-1 orthotopic xenograft-bearing mice.	Preclinical	(Emami et al., 2004; Arensman et al., 2014)
	PRI-724	The active enantiomer of ICG-001; Entered Phase 1 and 2 clinical trials for treating advanced cancers.	Phase 1 and 2 clinical trials	(ClinicalTrials.gov NCT01764477, NCT01302405, NCT01606579, NCT02413853)
Small molecule inhibitor blocking **β-catenin/p300** interaction	Windorphen	Suppressed *in vitro* proliferation of colorectal cancer cell lines SW480 and RKO and prostate cancer cell lines DU145 and PC3.	Discovery	(Hao et al., 2013)
Small molecule **PORCN** inhibitors, blocking Wnt secretion	IWPs		Discovery	(Chen et al., 2009)
	C59	Inhibited MMTV-Wnt1 tumor growth *in vivo*.	Preclinical	(Proffitt et al., 2013)
	LGK974	Induced regression of MMTV-WNT1 tumors; Inhibited *in vitro* colony formation of head & neck cancer cell line HN30 and *RNF43*-mutant pancreatic cancer cell lines Patu8988S and HPAF-II; Inhibited *in vivo* tumor growth in xenografts of HN30 and *RNF43*-mutant pancreatic cancer cell lines Capan2 and HPAF-II; Entered Phase 1 and 2 clinical trials for treating cancers.	Phase 1 and 2 clinical trials	(Jiang et al., 2013; Liu et al., 2013; ClinicalTrials.gov NCT01351103, NCT02278133, NCT02649530)

53

	ETC-159	Inhibited *in vitro* colony formation of teratocarcinoma cell lines PA-1 and *RNF43*-mutant pancreatic and ovarian cancer cell lines HPAF-II, AsPC-1, and MCAS; Suppressed *in vivo* tumor growth in xenografts of HPAF-II, AsPC-1,teratocarcinoma cell lines PA-1 and NCCIT, and patient-derived colorectal tumor xenografts with *RSPO3* fusions; Entered Phase 1 clinical trial for treating advanced cancers.	Phase 1 clinical trial	(Madan et al., 2016; ClinicalTrials.gov NCT02521844)
	RXC004	Suppressed *in vivo* tumor growth of Capan2 xenografts; Entered Phase 1 clinical trial for treating advanced cancers.	Phase 1 clinical trial	(Bhamra et al., 2017; ClinicalTrials.gov NCT03447470)
	CGX1321	Suppressed *in vivo* tumor growth of patient-derived gastric and colorectal tumor xenografts with *RSPO2* fusions; Entered Phase 1 clinical trial for treating advanced cancers.	Phase 1 clinical trial	(Li et al., 2018; ClinicalTrials.gov NCT03507998, NCT02675946)
Decoy Wnt receptor	Ipafricept (OMP-54F28)	Suppressed *in vivo* tumor growth of patient-derived hepatocellular carcinoma, pancreatic and ovarian cancer xenografts and decreased the cancer stem cell frequency; Entered Phase 1 clinical trials for treating advanced cancers; In a Phase 1 clinical trial, two desmoid tumor and a germ cell cancer patient treated with Ipafricept experienced stable disease for >6 months.	Phase 1 clinical trials	(Jimeno et al., 2017; ClinicalTrials.gov NCT02069145, NCT02092363, NCT02050178, NCT01608867)
Anti-Frizzled1,2,5,7,8 antibody	Vantictumab (OMP-18R5)	Suppressed *in vivo* tumor growth of patient-derived colorectal, breast, lung, and pancreatic tumor xenografts and PA-1 xenografts; Decreased the cancer stem cell frequency; Entered Phase 1 clinical trials for treating cancers.	Phase 1 clinical trials	(Gurney et al., 2012; ClinicalTrials.gov NCT01345201, NCT02005315, NCT01957007, NCT01973309)

Anti-Frizzled5,8 antibodies	IgG-2919, IgG-2921	Both antibodies suppressed *in vitro* proliferation of *RNF43*-mutant pancreatic cancer cell lines HPAF-II, Patu8988S, and AsPC-1, and led to cell cycle arrest; IgG-2912 suppressed *in vivo* tumor growth of HPAF-II and AsPC-1 xenografts and organoid formation of *RNF43*-mutant colorectal cancers.	Preclinical	(Steinhart et al., 2017)
Anti-LRP6 antibodies	A7-IgG, B2-IgG	A7-IgG specifically inhibited tumor growth of MMTV-Wnt1 xenografts; B2-IgG specifically inhibited tumor growth of MMTV-Wnt3 xenografts.	Preclinical	(Ettenberg et al., 2010)
Anti-RSPO antibodies	Anti-RSPO1 antibody, anti-RSPO2 antibody, anti-RSPO3 antibodies	Suppressed *in vivo* tumor growth of patient-derived colorectal, lung, and ovarian tumor xenografts with corresponding RSPO overexpression; Anti-RSPO3 antibody (OMP-131R10) has entered phase 1 clinical trial for treating advanced solid tumors and metastatic colorectal cancers.	Preclinical, phase 1 clinical trial (OMP-131R10)	(Chartier et al., 2016; Storm el al., 2016; ClinicalTrials.gov NCT02482441)

Table 3. Anti-Wnt signaling-based drug combinations in cancer therapy

Drug A	Drug B (Wnt pathway inhibitor)	Drug combination rationales/ Preclinical results	Clinical trials
Paclitaxel and carboplatin (chemo agents)	Ipafricept/OMP-54F28 (decoy Wnt recptor)	The drug combinations showed synergistic and potent tumor growth inhibition in patient-derived ovarian, pancreatic, hepatocellular, breast, lung, and/or colorectal cancer xenografts (Jimeno et al., 2017; Fischer et al., 2017; Chartier et al., 2016).	Phase 1 clinical trial (NCT02092363) in patients with recurrent platinum-sensitive ovarian cancer
Nab-paclitaxel and gemcitabine (chemo agents)			Phase 1 clinical trial (NCT02050178) in patients with previously untreated stage IV pancreatic cancer
Sorafenib (RAF, VEGFR, and PDGFR inhibitor)			Phase 1 clinical trial (NCT02069145) in patients with hepatocellular cancer
Paclitaxel (chemo agent)	Vantictumab/OMP-18R5 (anti-Frizzleds antibody)		Phase 1 clinical trial (NCT01973309) in patients with locally recurrent or metastatic breast cancer
Docetaxel (chemo agents)			Phase 1 clinical trial (NCT01957007) in patients with previously treated non-small-cell lung carcinoma
Nab-paclitaxel and gemcitabine (chemo agents)			Phase 1 clinical trial (NCT02005315) in patients with previously untreated stage IV pancreatic cancer
Taxol, gemcitabine, or irinotecan (chemo agents)	Anti-RSPO1, anti-RSPO2, and anti-RSPO3 antibodies		
FOLFIRI (chemo agents)	OMP-131R10 (anti-RSPO3 antibody)		Phase 1 clinical trial (NCT02482441) in patients with metastatic colorectal cancer
API2 (AKT inhibitor)	NVP-TNKS656 (tankyrase inhibitor)	Tankyrase inhibition reverted resistance to AKT inhibition in patient-derived colorectal cancer xenografts (Arques et al., 2016).	
Gefitinib or AZD9291 (EGFR inhibitors)	AZ1366 (tankyrase inhibitor)	The drug combination significant slowed down growth of non-small cell lung cancer orthotopic xenografts and improved	

		survival of tumor-bearing mice (Scarborough et al., 2017).	
Vemurafenib (BRAF inhibitor)	ICG-001 (blocking β-catenin/TCF interaction)	BRAF inhibition up-regulated β-catenin signaling in colorectal cancer cell lines *in vitro*. The drug combination led to synergistic tumor growth inhibition in HT29 xenografts (Chen et al., 2018).	
LGX818 (BRAF inhibitor) and Cetuximab (EGFR inhibitor)	LGK974 (PORCN inhibitor)	A subset of colorectal cancers harbor concurrent mutations in *BRAF* and *RNF43* or *RSPOs* (Yan et al., 2017).	Phase 1/2 clinical trial (NCT02278133) in patients with BRAF-mutant metastatic colorectal cancer with Wnt pathway mutations
Buparlisib/BKM120 (pan-PI3K inhibitor)	LGK974 (PORCN inhibitor)	Burparlisib treatment up-regulated Wnt signaling in triple negative breast cancer (TNBC) cell lines *in vitro*. The drug combination led to synergistic tumor growth inhibition in xenografts of TNBC cell line TMD231 (Solzak et al., 2017).	
Multiple PI3K/mTOR inhibitors including GDC-0941, ZSTK474, LY-294002, AS252424, and Ku0063794	ETC-159 (PORCN inhibitor)	ETC-159 in combination with one of the five PI3K/mTOR inhibitors synergistically suppressed 3D colony formation of several Wnt-addicted pancreatic and cholangiocarcinoma cell lines. ETC-159 in combination with GDC-0941 led to synergistic tumor growth inhibition in HPAF-II and AsPC-1 xenografts (Zhong et al., 2019).	
Olaparib (PARP inhibitor)	Pyrvinium (CK1α activator) or XAV939 (tankyrase inhibitor)	Wnt/β-catenin signaling mediated resistance to PARP inhibition in ovarian cancer due in part to up-regulation of DNA damage repair. Inhibition of β-catenin signaling reverted resistance to olaparib in ovarian cancer xenografts (Fukumoto et al., 2019; Yamamoto et al., 2019).	
Vismodegib (Hedgehog signaling inhibitor)	LGK974 (PORCN inhibitor) or anti-LRP6 antibody	A LGR5+ tumor cell population maintained by active Wnt signaling persists vismodegib treatment in human and	

|		mouse basal cell carcinoma and mediates relapse after treatment discontinuation. The drug combination reduced tumor burden (vismodegib + anti-LRP6 antibody) or eliminated resistant tumor cells (vismodegib + LGK974) in mouse models (Biehs et al., 2018; SanchezDanes et al., 2018).	
PDR001 (anti-PD1 antibody)	LGK974 (PORCN inhibitor)	Preclinical studies showed that Wnt signaling mediated resistance to immunotherapies, and concurrent inhibition of Wnt/β-catenin signaling enhanced the efficacy of immune checkpoint inhibitors in melanoma mouse models (Spranger et al., 2015; Holtzhausen et al., 2015; Zhao et al., 2018).	Phase 1 clinical trial (NCT01351103) in patients with malignancies dependent on Wnt ligands
Pembrolizumab (anti-PD1 antibody)	ETC-159 (PORCN inhibitor)		Phase 1 clinical trial (NCT02521844) in patients with advanced solid tumor
	CGX1321 (PORCN inhibitor)		Phase 1 clinical trial (NCT02675946) in patients with advanced gastrointestinal tumor

Figure 1

Figure 2

Figure 3